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Functions of the nervous system are accompanied at the cellular level by 
changes in gene expression, regulated by transcription factors and epigenetic 
mechanisms, such as histone modifications and DNA methylation, that are 
frequently  altered in neurological disorders. 5-hydroxymethylcytosine (5hmC), a 
recently identified DNA base derived from 5-methylcytosine, accounts for ~40% 
of modified cytosines in the neuronal genomes, suggesting that 5hmC is a stable 
epigenetic mark and its interpretation in the nervous system may differ from the 
other tissues. This hypothesis was supported by the recent findings showing that 
5hmC is enriched over the bodies of active genes within euchromatin in a cell-
specific manner. In the first part of this study, we identify the methyl-CpG binding 
protein 2 (MeCP2) as the major reader of this activation mark and demonstrate 
that MeCP2 is the only methyl-CpG binding domain (MBD) protein that binds 
5hmC and, 5mC, with high affinity. We reveal strong preferential inhibition of 
MeCP2 affinity to 5hmC by a Rett-syndrome-causing mutation, R133C. We then 
show that MeCP2 recognizes 5hmC and 5mC within CpA context. Modified CpAs 
were recently shown to exist in embryonic stem and neuronal cells, where it 
localizes to actively transcribed gene bodies. Together these data support a 
model where 5hmC  and MeCP2 formulate a cell-specific epigenetic mechanism 
for establishing active chromatin states that facilitate gene expression. This is 
supported by our observation of reduced chromatin accessibility of 5hmC 
containing loci in the absence of MeCP2.
In the second part of the study, we discover a complex in the brain nuclear 
extract that assembles specifically in the presence of 5hmC. We purify and 
identify components of this complex: the purine-rich element binding protein (Pur) 
α and β, which are required for the proper development of neuronal cell types. 
We verify the increased affinity of recombinant Purα and Purβ  to 5hmC and 
support a binding mechanism where they separate two strands of DNA and 
recognize specific sequences. These findings offer a previously unknown 
function for Pur proteins via binding to 5hmC. 
This study presents new decoders of a novel epigenetic mark, 5hmC, that is 
effectively and differentially employed in the brain. Unlike previous studies, we 
introduce readers of 5hmC  as a stable activation mark. In addition, by 
mechanistic characterization of our model we link 5hmC to an autism spectrum 
disorder and offer a new avenue toward investigation of its pathophysiology.
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Chapter I.
Introduction
I.I. Prologue: from brain to chromatin
! Understanding how the brain works is one of the most exciting scientific 
quests of our age. The study of the nervous system started over a century ago 
with the identification of individual neuron as its “absolutely  autonomous unit” by 
Ramón y Cajal (Ramon y Cajal 1899; Ramón y Cajal 1917). We now know that 
the mammalian central nervous system (CNS) is a highly sophisticated network 
made of hundreds of distinct classes of neurons and glia, nourished by blood 
vessels (Jones, Stone et al. 2011; Reid 2012). 
The basic function of a neuron is to receive a chemical/physical signal at its 
dendritic extensions or its cell body; convert it into an electrical signal by 
manipulating ion gradient across its membrane; and transmit the so-called action 
potential to its destination on the axon where it is converted into a chemical 
signal by the release of signaling molecules for its target cell (Kandel, Schwartz 
et al. 2000). Neurons can be classified into hundreds of types, each with unique 
sets of functions and distinct anatomical, molecular and electrochemical profiles 
(Masland 2004; Lichtman, Livet et al. 2008). Glia, which far outnumber the 
neurons (Kandel, Schwartz et al. 2000), are housekeepers, insulators and nurses 
of the neurons. Some are also thought to participate in neurotransmission and to 
surveil, sculpt and modulate synaptic connections (Allen and Barres 2009; 
Graeber 2010). 
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The diversity of cell types in the CNS and their complex interconnectivity is 
established by  their unique collection of expressed genes (Nelson, Sugino et al. 
2006). Since the genomic information is identical in every cell, organisms use 
transcription factors aided by “epigenetic”, or “outside conventional genetic”, 
mechanisms that formulate these characteristic gene expression profiles 
(Jaenisch and Bird 2003). Epigenetic mechanisms include changes in the 
chemical, physical and topological characteristics of the chromatin, where the 
genomic information resides. These changes cause a discrepancy in the nuclear 
architecture that is readily visible under microscope: not only in the aggregation 
pattern of chromatin; but also in the structure of the nuclear envelope, in the 
distribution of nuclear pores and nuclear bodies. (Takizawa and Meshorer 2008). 
Chromatin is a three-dimensional structure, made of DNA, histones and other 
architectural factors. The most obvious form of its structural organization is the 
compartmentalization into “euchromatin” and “heterochromatin”, as first 
described almost a century ago (Heitz 1928). Heterochromatin encompasses 
highly condensed regions where the genomic material is inaccessible and 
therefore “silent”; whereas euchromatin appears decondensed and contains 
actively expressed regions of genetic material. For instance, Purkinje cells (PCs), 
which are among the largest cells in the brain, have large nuclei and store only 
10% of their DNA in heterochromatin in the center of their nucleus (Fig 1.1). In 
contrast, the nuclei of granule cells (GCs) are small, compact and display ~64% 
of their genome in large aggregates heterochromatin that are scattered in the 
nuclear periphery (Palay and Chan-Palay 1974; Lafarga, Berciano et al. 1991).
2
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I.II. Chromatin: the nucleoprotein 
! Historical perspectives, which considered chromatin to be a static, 
unchanging entity, have been replaced by the current appreciation of its modular, 
complex and highly plastic nature. The basic building unit of chromatin is the 
nucleosome, which is formed by wrapping ~146 base pairs (bp) of DNA around a 
histone core, which consists of two copies of each histone proteins, H2A, H2B, 
H3 and H4 (Fig 1.2) (Hamon and Cossart 2008; Takizawa and Meshorer 2008). 
Each histone protein contains a globular part and an unstructured N-terminal tail 
that protrudes from the nucleosome (Luger, Maeder et al. 1997; Andrews and 
Luger 2011). These tails can accommodate a variety of chemical modifications 
that can influence local protein composition, arrangement of nucleosomal arrays 
and histone-DNA interactions. The combinatorial nature of histone modifications 
reveals a “histone code” that defines chromatin states (Jenuwein and Allis 2001; 
Andrews and Luger 2011). For example, euchromatin is normally marked with 
histone H3 trimethylated on lysine 4 (H3K4me3) and acetylated on lysine 9 
(H3K9ac); while H3K9me3 and H4K20me3 are concentrated in constitutive 
heterochromatin and H3K27me3 in facultative heterochromatin. Global structure 
of the chromatin is also regulated by other proteins, such as chromatin 
remodeling enzymes, transcriptional activators and repressors, architectural 
proteins, and the “linker histone”, H1, that binds the “linker DNA” bridging two 
adjacent nucleosomes, (Misteli 2001).
4
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I.III. Chromatin: nucleic acid modifications 
! Chromatin states are largely  established by chromatin-associated factors; 
however they also can be influenced at base resolution by direct chemical 
modifications of DNA. Although nucleic acid of various organisms accommodates 
over 100 modified bases, in the mammalian DNA, the principle DNA modification 
seemed to be the methylation of cytosines (Cs) in symmetric CpG dinucleotides 
(5-methylcytosine, 5mC or “the fifth base”) (Bird 2002; Ratel, Ravanat et al. 
2006). Today, non-CpG methylation (Ramsahoye, Biniszkiewicz et al. 2000; 
Pastor, Pape et al. 2011) and oxidation products of 5mC, primarily 5-
hydroxymethylcytosine (5hmC or “the sixth base”) (Kriaucionis and Heintz 2009; 
Tahiliani, Koh et al. 2009; Ito, Shen et al. 2011), are also accepted as major 
mammalian DNA modifications. Other epigenetic mechanisms at the nucleic acid 
level include the occurrence of these modifications in the mitochondria (Pollack, 
Kasir et al. 1984; Dzitoyeva, Chen et al. 2012) and also a complex realm of non-
coding RNAs (Mehler and Mattick 2007; Satterlee, Barbee et al. 2007).
I.IV. 5mC: discovery, genomic distribution and function
! 5mC entered the scientific vocabulary almost a century ago (Johnson and 
Coghill 1925) and its presence in the mammalian genome was discovered 25 
years later (Wyatt 1950). It also is found in the genome of other vertebrates, 
flowering plants, invertebrates, protists, fungi and bacteria (Goll and Bestor 
2005). Interestingly, the invertebrate-vertebrate boundary marks a distinctive 
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evolutionary shift from a fractional to a global methylation pattern, where almost 
all gene bodies are methylated in vertebrates (Tweedie, Charlton et al. 1997).
Eukaryotic DNA methylation is now recognized to be a chief contributor to the 
silent chromatin state and inhibition of gene expression (Jaenisch and Bird 2003; 
Ooi, O'Donnell et al. 2009). Strong evidence for the silencing role of 5mC comes 
from its high levels in the heterochromatin and in the repeat elements that are 
thus stabilized (Doskocil and Sorm 1962; Keshet, Lieman-Hurwitz et al. 1986). 
Another major manifestation of this role is the X chromosome inactivation, where 
the silent X is invariably  hypermethylated (Riggs 1975; Heard, Clerc et al. 1997; 
Walsh, Chaillet et al. 1998). In the early  studies, artificially methylated transgenes 
inserted into mouse cells were repressed (Stein, Razin  et al. 1982). Conversely, 
chemical inhibition of methylation reverses the silencing of previously  methylated 
genes (Groudine, Eisenman et al. 1981; Mohandas, Sparkes et al. 1981).  
In silent chromatin, 5mC  is found as a permanent mark; whereas differentially 
methylated regions (DMRs) are regulated in a cell-specific manner (Song, Smith 
et al. 2005; Hahn, Wu et al. 2011; Lister, Pelizzola et al. 2009) in concert with the 
repressive histone signal H3K9me3. Accordingly, activating histone marks, such 
as H3K27me3, H3K4me and H2A.Z variant, are excluded from methylated 
regions (Meissner, Mikkelsen et al. 2008; Zilberman, Coleman-Derr et al. 2008; 
Laurent, Wong et al. 2010; Coleman-Derr and Zilberman 2012). In many cancer 
cells, aberrant methylation patterns are frequently  observed (Ting, McGarvey et 
al. 2006; Irizarry, Ladd-Acosta et al. 2009).
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I.V. CpG dinucleotide and beyond
! In mammals, the predominant form of DNA methylation occurs 
symmetrically  within CpG dinucleotides and it comprises 70-80% of these 
dinucleotides (Bird, Taggart et al. 1985). Interestingly, CpG-rich regions (CpG 
islands or CGIs), which are found within promoter regions of 70% of human 
genes, contain very  low amounts of methylation (Bird, Taggart et al. 1985; 
Saxonov, Berg et al. 2006). However, these may become methylated if the gene 
needs to be repressed in the course of development (Li, Beard et al. 1993) or 
differentiation (Song, Smith et al. 2005). Cytosine methylation is also a prominent 
cause of mutations. In humans, the mutation rate from 5mC to thymine (T) is 
10-50 fold higher than other transitions (Duncan and Miller 1980), causing the 
CpG dinucleotide to be present only at 20% of its expected frequency (Sved and 
Bird 1990). The deamination of one 5mC in a CpG dinucleotide generates a 
5mCpG‧TpG mismatch (Wiebauer and Jiricny 1989), which can then be 
“corrected” to a CpA by thymine DNA glycosylase (TDG) (Neddermann, Gallinari 
et al. 1996).
Until recently, the methylation studies were focused on the CpG dinucleotide but 
newer studies revealed that non-CpG methylation, primarily CpA methylation, 
constitutes 20-25% of genome-wide methylation in mammalian pluripotent and 
differentiated cells (Ramsahoye, Biniszkiewicz et al. 2000; Lister, Pelizzola et al. 
2009; Laurent, Wong et al. 2010). CpA methylation is reduced at promoters but 
highly enriched in the gene bodies exhibiting strong correlation with gene 
expression, whereas no such correlation is observed for CpG methylation (Lister, 
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Pelizzola et al. 2009; Laurent, Wong et al. 2010). Non-CpG methylation in gene 
bodies is asymmetrical almost at all times, even in CHG context, and is 
significantly enriched on the antisense strand. The expanded context of non-CpG 
context is TACA(A/T), with a periodicity  of 8-10 bp  between modified Cs 
corresponding to a single turn of the DNA helix (Lister, Pelizzola et al. 2009). 
Thus a pattern, where methyl groups aligned linearly  on the DNA strand, 
becomes obvious and may be definitive in coordination of methylation-specific 
proteins. 
I.VI. Dnmts: enzymes in the making of 5mC
! 5mC is generated by the covalent addition of a methyl group from S-
adenosyl-L-methionine (SAM) to the 5 position of cytosine by a DNA 
methyltransferase, Dnmt (Fig 1.3) (Santi, Garrett et al. 1983; Bestor 2000; Lin 
2011). The originally cloned Dnmt was the “maintenance” methyltransferase, 
Dnmt1, that methylates hemimethylated CpG dinucleotides during replication 
(Bestor and Ingram 1983). Later, de novo methyltransferases, Dnmt3a and 
Dnmt3b, were discovered which can methylate both unmethylated and 
hemimethylated target sequences (Bestor and Ingram 1983; Bestor 1988; Mund, 
Musch et al. 2004). The last family  member, Dnmt2, has only weak activity 
toward DNA and is now accepted to be an RNA methylase (Okano, Xie et al. 
1998; Mund, Musch et al. 2004). 
9
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Dnmt1 is recruited to replication fork via ubiquitin-like plant homeodomain and 
RING finger domain 1 (Uhrf1) that recognizes hemimethylated DNA, whereas de 
novo methyltransferases bind DNA directly independent of its modification status 
(Bostick, Kim et al. 2007; Sharif, Muto et al. 2007). Dnmts are frequently found 
associated with heterochromatin regions in a cell-cycle-independent manner 
(Bachman, Rountree et al. 2001; Hermann, Goyal et al. 2004). Non-CpG 
methylation is thought to be carried out by Dnmt3a (Ramsahoye, Biniszkiewicz et 
al. 2000; Mund, Musch et al. 2004; Laurent, Wong et al. 2010; Arand, Spieler et 
al. 2012), although a role for Dnmt1 was also proposed based on the inheritance 
of non-CpG methylome (Grandjean, Yaman et al. 2007). 
Dnmt3b is expressed within a narrow window during embryogenesis, whereas 
Dnmt1 and Dnmt3a are present throughout life (Okano, Bell et al. 1999). The 
absence of Dnmts can lead to global DNA hypomethylation, chromosomal 
instability and aberrant cell-cycle progression, although they are not required for 
embryonic stem (ES) cell integrity or self-renewal (Tsumura, Hayakawa et al. 
2006). Nevertheless, the deletion of Dnmt1 or Dnmt3b in mice results in 
embryonic lethality (Li, Bestor et al. 1992), while Dnmt3a -/- mice survive up to 4 
weeks with normal methylation in heterochromatic regions (Okano, Bell et al. 
1999) and Dnmt2 -/- does not have a phenotype (Okano, Xie et al. 1998). 
Mutations in the DNMT3B gene has been linked to instability  facial anomalies 
(ICF) syndrome in humans (Okano, Bell et al. 1999). 
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I.VII. Dnmts in the brain
! The majority  of DNA methylation mechanisms have been characterized in 
ES cells yet their influence on the CNS remains unclear. For instance, multiple 
isoforms of de novo methyltransferases are expressed in ES cells, but only full-
length variant of Dnmt3a is found at high levels and in diffuse pattern in neurons 
(Feng, Chang et al. 2005; Nguyen, Meletis et al. 2007), suggesting that 
euchromatic de novo methylation might be specifically  needed for neuronal 
functions. Indeed, nonpromoter methylation by Dnmt3a promotes transcription of 
neural genes (Wu, Coskun et al. 2010) and regulates cellular and behavioral 
plasticity in response to emotional stimuli in mice (LaPlant, Vialou et al. 2010). 
Moreover, after fear conditioning, Dnmt3a levels double whereas Dnmt1 level is 
unchanged, indicative of an interplay between neuronal activity and euchromatic, 
nonpromoter, Dnmt3a-mediated methylation (Miller and Sweatt 2007). 
The lethality of the Dnmt-knockouts in the early stages of life necessitated 
alternative approaches for the study of methylation in postmitotic cells. Initially, 
pharmacological Dnmt inhibitors were used, such as RG108 (Brueckner, Garcia 
Boy et al. 2005), a competitive Dnmt1 inhibitor, or 5-azacytidine (Creusot, Acs et 
al. 1982; Miller and Sweatt 2007) and zebularine (Levenson, Roth et al. 2006; 
Miller, Gavin et al. 2010). Since the latter two chemicals are incorporated into the 
DNA after replication, in non-dividing cells they did not pan out to be useful.
In later studies, a brain-restricted knockout of Dnmt1 resulted in an estimated 
50% loss of methylation and produced mutant neurons and glia (Fan, Beard et al. 
2001;  Golshani, Hutnick et al. 2005). However when Dnmt1 was inactivated in 
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the adult brain, global DNA methylation and cell survival were unaffected (Fan, 
Beard et al. 2001). Deletion of Dnmt3a in the developing CNS leads to 
neuromuscular defects and shortens lifespan (Nguyen, Meletis et al. 2007), 
whereas in its postnatal ablation in excitatory neurons long-term plasticity, 
learning and memory are impaired, by upregulation of immune genes (Feng, 
Zhou et al. 2010) that are considered breaks of synaptic plasticity (Shatz 2009).
I.VIII. MBDs: 5mC-binding proteins
! The widely accepted role for 5mC is to displace some DNA binding 
proteins and to recruit methylation specific proteins (Watt and Molloy 1988; Klose 
and Bird 2004). The first “activity that could bind methylated DNA in solution” was 
methyl-CpG binding protein (MeCP) (Meehan, Lewis et al. 1989), that turned out 
to be a multiprotein complex, MeCP1 (Ng, Zhang et al. 1999; Feng and Zhang 
2001). In contrast, another such activity, MeCP2, was a single polypeptide 
(Lewis, Meehan et al. 1992) with an 80 amino acid methyl-CpG binding domain 
(MBD), which is necessary and sufficient for recognition of 5mC (Nan, Meehan et 
al. 1993; Nan, Tate et al. 1996; Nan, Campoy et al. 1997). A database search 
revealed four additional proteins that contain the consensus MBD sequence: 
MBD1 through MBD4 (Hendrich and Bird 1998; Dhasarathy and Wade 2008). 
Among the MBD family of proteins, MBD1 acts as a transcriptional repressor by 
recruiting histone deacetylases (HDACs) upon binding both to 5mC with its MBD 
and to unmodified DNA with one of its three zinc-coordinating CXXC domains 
(Fujita, Shimotake et al. 2000; Jorgensen, Ben-Porath et al. 2004). MBD2 and 
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MBD3 share 70% sequence identity and are thought to have arisen through gene 
duplication (Hendrich and Bird 1998; Hendrich and Tweedie 2003). MBD3 is the 
only MBD protein that does not recognize 5mC (Zhang, Ng et al. 1999) due to 
two amino acid substitutions in the MBD (Fraga, Ballestar et al. 2003). It is a core 
component of nucleosome remodeling and histone deacetylase repressor 
(NuRD) complex (Saito and Ishikawa 2002), which is recruited to DNA by MBD2 
(Feng and Zhang 2001). Together they make up the MeCP1 complex. MBD4 
appears to play a key  role in DNA repair, by preferentially  binding to and 
processing a 5mCpG‧TpG mispair with its glycosylase domain (Hendrich, 
Hardeland et al. 1999). 
A recent comparative analysis identified six additional proteins that contain an 
MBD: MBD5, MBD6, BAZ2A, BAZ2B, SETDB1 and SETDB2 (Roloff, Ropers et 
al. 2003). Most of these proteins do not show specificity  for methylated DNA 
except SETDB1 (Gou, Rubalcava et al. 2010), and their functions vary (Hendrich 
and Tweedie 2003; Laget, Joulie et al. 2010). A novel 5mC binding protein, 
Kaiso, lacks MBD, but recognizes 5mC through zinc finger domains, and 
mediates repression by  associating with the NCoR complex (Hendrich and Bird 
1998; Prokhortchouk, Hendrich et al. 2001; Yoon, Chan et al. 2003).
I.IX. MBDs in the brain
! The phenotypic deficits in Mbd1 -/- mice are restricted to CNS, specifically 
in learning, memory and plasticity, due to reduced neuronal differentiation and 
increased genomic instability (Zhao, Ueba et al. 2003). Mbd2 -/- mice show minor 
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behavioral deficits whereas deletion of Mbd3 is embryonic lethal (Hendrich, Guy 
et al. 2001). A role for MBD3 in the neuronal development was suggested since 
its levels are regulated throughout developing brain, unlike MBD2 which displays 
minimal expression in the embryonic brain (Jung, Zhang et al. 2003). There is 
clinical evidence that links MBD5 to mental disorders (Williams, Mullegama et al. 
2010; Noh and Graham Jr 2012), however the mechanism is still unclear. 
Although Setdb1 -/- mice seem normal (Jiang, Matevossian et al. 2011) and the 
Setdb1 gene is expressed at very low levels in the CNS, its histone 
methyltransferase activity might be required for proper CNS functioning (Ryu, 
Lee et al. 2006; Jiang, Matevossian et al. 2011). Finally, despite the fact that the 
X-linked Kaiso gene is highly expressed in the brain, it was not linked to CNS 
dysfunction (Della Ragione, Tiunova et al. 2006; Prokhortchouk, Sansom et al. 
2006).
I.X. MBDs: the curious case of MeCP2
! MeCP2 constitutes a unique case within the neuronal epigenetic 
mechanisms, because of its abundance, enigmatic functions and the clinical 
manifestation of its dysfunction. MeCP2 is present in all vertebrates and is in fact 
a “vertebrate invention” (Bird, A., personal communication). The expression of 
MeCP2 in mice is low at birth, increases greatly in the first three weeks and 
plateaus when it is expressed near nucleosome levels in the brain (Kishi and 
Macklis 2004; Skene, Illingworth et al. 2010). It is also expressed to some extent 
in the lung and spleen (Shahbazian, Young et al. 2002).
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• Structure and disorder in MeCP2
The full-length human MeCP2 is 60% unstructured, and its secondary structure is 
stabilized upon binding to DNA or proteins (Adams, McBryant et al. 2007; Ghosh, 
Nikitina et al. 2010). The X-ray structure of MeCP2 MBD with a 5mCpG-
containing DNA (Wakefield, Smith et al. 1999) revealed that 5mC and MBD make 
multiple contacts, several of which are maintained by immobilized water 
molecules in the major groove of the double helix (Ho, McNae et al. 2008). 
Although MeCP2 exists strictly as a monomer in solution (Ghosh, Horowitz-
Scherer et al. 2010), it can form clusters upon binding to methylated DNA 
(Nikitina, Ghosh et al. 2007). MeCP2 affinity to DNA increases with the length of 
the DNA independent of methylation (Nan, Hou et al. 2007).
In addition to MBD, MeCP2 also contains a basic N-terminal domain with two 
consensus A/T-hook motifs which bind the minor groove of A/T-rich duplex DNA 
(Adams, McBryant et al. 2007), and a C-terminal TRD domain that can interact 
with several factors, including transcription repressors, HDACs, NCoR, mSin3a 
and CoREST; transcription activators, YY1, YB1, CREB and Brahma; and 
heterochromatin associated factors, HP1, Dnmt1 and Atrx (Nan, Ng et al. 1998; 
Kokura, Kaul et al. 2001; Fuks, Hurd et al. 2003; Harikrishnan, Chow et al. 2005; 
Young, Hong et al. 2005; Agarwal, Hardt et al. 2007; Chahrour, Jung et al. 2008; 
Forlani, Giarda et al. 2010). The functions of these interactions remain elusive.
• MeCP2:  a transcriptional repressor, or activator?
Several biochemical and chromatin immunoprecipitation (ChIP) experiments 
showed that MeCP2 avidly  binds methylated DNA (Lewis, Meehan et al. 1992; 
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Gregory, Randall et al. 2001; Skene, Illingworth et al. 2010), which is associated 
with gene silencing. The direct involvement of MeCP2 in transcriptional 
repression by a methylation dependent mechanism was demonstrated in cell 
culture studies (Boyes and Bird 1991; Nan, Campoy et al. 1997; El-Osta, 
Kantharidis et al. 2002) and later in reconstituted systems in Drosophila 
melanogaster, which lacks genomic methylation (Kudo 1998). In cortical cultures 
MeCP2 can associate with some neural genes, such as Bdnf (Chen, Chang et al. 
2003; Kernohan, Jiang et al. 2010), and this interaction is lost upon stimulation 
with KCl (Harikrishnan, Bayles et al. 2010; Tian, Marini et al. 2010), leading to 
increased expression (Martinowich, Hattori et al. 2003). 
The widely accepted role of MeCP2 as a transcriptional repressor was 
challenged with the availability of Mecp2 -/- mice: First, a brain-restricted deletion 
of Mecp2 resulted only in subtle changes in gene expression (Tudor, Akbarian et 
al. 2002; Jordan, Li et al. 2007) and the search for genes that are repressed by 
MeCP2, has so far identified only a few targets (Nuber, Kriaucionis et al. 2005; 
Kriaucionis, Paterson et al. 2006; Jordan, Li et al. 2007). Later analyses of gene 
expression in hypothalami and cerebella of Mecp2-deficient and Mecp2-
overexpressing mice, revealed that the majority  of genes were activated by 
MeCP2 (Chahrour, Jung et al. 2008; Ben-Shachar, Chahrour et al. 2009). Some 
groups also reported MeCP2-dependent changes in gene splicing (Young, Hong 
et al. 2005), microRNA profiles (Urdinguio, Fernandez et al. 2010), and 
transcription of repetitive elements (Skene, Illingworth et al. 2010). Thus a more 
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complex role for MeCP2 was proposed, where it dampens transcriptional noise 
as a buffer and/or regulates transcription depending on the molecular context.
• Where is MeCP2?
The early studies showed that MeCP2 localizes in heterochromatic foci (Hendrich 
and Bird 1998), that it can stably associate with nucleosomes with methylated 
DNA and linker DNA (Chandler, Guschin et al. 1999; Yang, van der Woerd et al. 
2011), and that it can facilitate chromatin compaction (Georgel, Horowitz-Scherer 
et al. 2003; Nikitina, Ghosh et al. 2007; Nikitina, Shi et al. 2007). In addition, 
absence of Mecp2 caused a normally  silent chromatin loop  to shift into an active 
chromatin state (Horike, Cai et al. 2005). Hence an alternative/additional role was 
advocated for MeCP2 in the management of the higher order chromatin 
landscape. 
To the contrary, in two independent genome-wide analyses, MeCP2 was found 
broadly distributed over the genome and not localized at discrete sites, such as 
heterochromatic regions or promoters of repressed genes (Yasui, Peddada et al. 
2007; Skene, Illingworth et al. 2010). Yet if MeCP2 covers the whole genome and 
its primary role is the organization of heterochromatin, then one would wonder 
why not all genome is condensed. Indeed, upon reexamination of nuclear 
staining of MeCP2 (LaSalle and Gerald 2004; Nan, Hou et al. 2007), it is evident 
that at heterochromatic foci MeCP2 is dense, as is DNA. The hypothesis that 
MeCP2 broadly covers the genome gained more support as more evidence 
came to light. For instance, in the absence of both Mecp2 and Dnmts, the 
chromatin structure undergoes global changes, including altered histone 
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acetylation and doubling of histone H1 (Nan, Campoy et al. 1997; Shahbazian, 
Young et al. 2002; Skene, Illingworth et al. 2010), not only in neurons but also in 
glia (Ballas, Lioy et al. 2009). This is complimentary to the observation that 
histone H1 levels in neurons are 50% less than in other cell types (Pearson, 
Bates et al. 1984) and that MeCP2 can compete with H1 on nucleosomes 
containing methylated DNA (Ghosh, Horowitz-Scherer et al. 2010). Together 
these results imply a histone H1-like role for MeCP2. 
In a recent study, a population of MeCP2 was found in chromatin regions that 
contain high levels of nucleosome and a second loosely-bound population in 
euchromatin. This second population was unique to the brain and absent in other 
tissues, suggesting a tissue-specific functional compartmentalization of MeCP2 
(Thambirajah, Ng et al. 2011). An earlier chromatin fractionation study from 
cultured human cells showed that the majority  of MeCP2 is present in the more 
nuclease-accessible, active regions of chromatin, while a small portion was 
associated with heterochromatin (Ishibashi, Thambirajah et al. 2008). Intriguingly, 
in the absence of Mecp2, the size of neuronal nuclei fails to increase at normal 
rates during differentiation and transcription is attenuated (Yazdani, Deogracias 
et al. 2012), both indicative of involvement of MeCP2 in the configuration of 
euchromatin state. The association of MeCP2 with active genes and active 
chromatin may seem to contradict its widely accepted role in repression and 
heterochromatin. However they  can also simply  be the manifestations of a 
dynamic, temporally dependent and activity-dependent function (Metivier, Gallais 
et al. 2008).
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• Rett Syndrome: A direct link to MeCP2 dysfunction
It was not too long after discovery  of MeCP2 that it was directly  linked to Rett 
Syndrome (RTT) (Amir, Van den Veyver et al. 1999). Being an X-linked gene; 
mutations of MECP2 affect males much more severely than girls, which exhibit 
mosaicism in heterozygocity after one X-chromosome is inactivated during 
dosage compensation (Adler, Quaderi et al. 1999). In line with the expression 
pattern of MeCP2, the symptoms of RTT arise only after 6-18 moths of age in 
girls: loss of speech, loss of purposeful hand use, stereotypical movements, 
seizures, mental retardation and hyperventilation. Only  few boys are diagnosed 
as they die within two years of birth (Hagberg, J et al. 1983). In postmortem brain 
tissue from RTT patients, lower spine density in hippocampal pyramidal neurons 
was observed (Chapleau, Calfa et al. 2009). Neurons, derived from induced 
pluripotent stem cells generated from RTT patientsʼ fibroblasts, had reduced 
spine density, smaller cell body and electrophysiological defects (Marchetto, 
Carromeu et al. 2010; Cheung, Horvath et al. 2011). 
Several deletions and mutants of MeCP2 have been created in mice (Chen, 
Akbarian et al. 2001; Guy, Hendrich et al. 2001; Pelka, Watson et al. 2006). 
Although heterozygous females acquire some phenotypes only in older ages; 
homozygous females and hemizygous males exhibit RTT symptoms at 5 weeks 
and die between 6 and 12 weeks. (Guy, Hendrich et al. 2001). Brain-specific 
deletion of Mecp2 during or after development results in full knockout phenotype 
(Chen, Akbarian et al. 2001; Nguyen, Du et al. 2012), as mice carrying MeCP2 
with RTT-causing mutations (Shahbazian, Young et al. 2002; Lawson-Yuen, Liu 
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et al. 2007). In these mice, the gross brain architecture is normal, indicating that 
MeCP2 is not required for neurodevelopment. However smaller and densely 
packed nuclei and cell bodies were obvious. The spine number and dendritic 
complexity  was also reduced (Na and Monteggia 2011), in agreement with a cell 
culture study, showing loss of Mecp2 leads to reduction in synapse numbers, 
which is reversed upon gain of Mecp2 (Chao, Zoghbi et al. 2007). In the absence 
of MeCP2, inhibitory activity increases and excitatory activity  decreases resulting 
in cortical dysfunction (Dani, Chang et al. 2005). 
Overexpression of Mecp2 only by two-fold initially results in enhanced learning 
and plasticity (Collins, Levenson et al. 2004). At 20 weeks of age neurological 
symptoms start to appear and mice have shorter life span. Serine-421 (S421) of 
MeCP2 was initially identified as an activity induced phosphorylation site that 
displaces MeCP2 from DNA (Zhou, Hong et al. 2006); however a S421A 
mutation changed neither the genome-wide binding of MeCP2 in vivo nor the 
expression of specific genes. The mice carrying these mutations exhibited 
defects in synapse development in cortical pyramidal neurons and mild 
behavioral abnormalities (Cohen, Gabel et al. 2011). In another study, the S421A/
S424A double mutants exhibited overexpression phenotypes (Li, Zhong et al. 
2011). S80 is ubiquitously phosphorylated, but this is lost upon neural stimulation 
(Tao, Hu et al. 2009). Mice carrying S80A mutation show mild phenotypes, and 
DNA binding of MeCP2 is attenuated.
Deletion of Mecp2 in inhibitory (Chao, Chen et al. 2010) and excitatory (Samaco, 
Hogart et al. 2005) neurons, as well as in confined regions in the brain 
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(Bissonnette and Knopp  2006; Gemelli, Berton et al. 2006; Fyffe, Neul et al. 
2008), mimics various aspects of the disease in mice. Complementary to these 
results, full reactivation of Mecp2 in its original levels and partial reactivation in 
neuron subpopulations reverses some or all phenotypes (Collins, Levenson et al. 
2004; Luikenhuis, Giacometti et al. 2004; Giacometti, Luikenhuis et al. 2007). 
Mecp2 -/- astrocytes cause abnormalities in neurons (Ballas, Lioy et al. 2009; 
Maezawa, Swanberg et al. 2009), and reactivation of Mecp2 in astrocytes in null 
mice reverses majority of the disease phenotypes (Lioy, Garg et al. 2012). 
Interestingly, hippocampal neurons treated with conditioned medium obtained 
from Mecp2-null microglia, which release five-fold higher glutamate, develop 
abnormally  (Maezawa and Jin 2010); and transplantation of WT myeloid cells 
into Mecp2 -/- mice arrests major symptoms of RTT (Derecki, Cronk et al. 2012).
In summary, MeCP2 and RTT present a particular case of the epigenetics of the 
brain that is fundamentally  different from other tissues. Here, subtle changes at 
the molecular level have severe consequences. Now, the addition of 5hmC to the 
vocabulary of brain epigenetics may provide more insight into the complexity of 
the mechanisms that sustain the CNS. 
I.XI. 5hmC: discovery, genomic distribution and function
! The existence of 5hmC in the mammalian genome was re-discovered 
during a comparative study of the genomic 5mC content between large and 
decondensed PC nuclei and compact GC nuclei (Fig 1.1), 60 years after its first 
discovery in T2 bacteriophages (Wyatt and Cohen 1952; Warren 1980; 
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Kriaucionis and Heintz 2009). Its presence in the mammalian brain was initially 
suggested (Penn, Suwalski et al. 1972), but this was not reproduced by others 
(Kothari and Shankar 1976; Gommers-Ampt and Borst 1995). 
5hmC levels in the brain range from 0.4 to 0.65 % of all Cs, whereas kidney, lung 
and muscle tissue exhibit “medium” levels, and finally  lowest levels are detected 
in the spleen, liver and testis. In contrast, 5mC levels are constant at 4-5 % in a 
variety of tissues (Globisch, Münzel et al. 2010). The change in the amount of 
5mC between cell populations was complementary to the levels of 5hmC 
suggesting that 5mC  and 5hmC may be derived from each other (Kriaucionis and 
Heintz 2009). 
5hmC is invariably enriched on euchromatin regardless of the cell type or 
developmental stage tested (Ficz, Branco et al. 2011; Szulwach, Li et al. 2011). 
For instance, on metaphase chromosomes, 5hmC is located on chromosome 
arms but depleted on centromers that contain high levels of 5mC (Szulwach, Li et 
al. 2011). 5hmC levels are highest within globally  decondensed nuclei enriched in 
active chromatin, such as those of ES cells or PCs (Meshorer and Misteli 2006; 
Kriaucionis and Heintz 2009; Tahiliani, Koh et al. 2009). The localization of 5hmC 
within the “on” state of chromatin implies that it may be involved in gene 
activation. Indeed gene bodies, promoters, transcription start sites (TSSs) and 
enhancer elements of active genes in ES cells have elevated levels of 5hmC, 
that strongly tracks with active enhancer marks, p300, H3K4me1, H3K4me2, 
H3K18ac and H3K27ac, and is mostly excluded from heterochromatin marks 
H3K27me3 (Ficz, Branco et al. 2011; Pastor, Pape et al. 2011; Stroud, Feng et al. 
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2011; Szulwach, Li et al. 2011; Wu, D'Alessio et al. 2011; Booth, Branco et al. 
2012; Yu, Hon et al. 2012). Intriguingly, extensive strand-bias was detected in 
methylomes and hydroxymethylomes of ES cells largely in non-CpG context 
(Ficz, Branco et al. 2011), which increased in the absence of Uhrf1,Tet1 and Tet2; 
suggesting that Dnmt3a or Dnmt3b with Tet3, or other putative enzymes might be 
required for asymmetric hydroxymethylation. 
In tissue samples 5hmC levels correlate with the differentiation state of cells, 
increasing toward terminally differentiated layers in hierarchically organized 
tissues and mainly enriched in gene bodies (Münzel, Globisch et al. 2010; 
Haffner, Chaux et al. 2011; Song, Szulwach et al. 2011; Orr, Haffner et al. 2012). 
Aberrant hydroxymethylation patterns are observed in both imprinting disorders 
and cancer (Haffner, Chaux et al. 2011).
The function of 5hmC still remains unclear: an intermediate in active or passive 
demethylation pathways, or a bona fide epigenetic mark. It is now widely 
accepted that 5hmC is passively demethylated in dividing cells, since Dnmt1 
does not recognize hemihydroxymethylated DNA as substrate (Valinluck and 
Sowers 2007; Hashimoto, Liu et al. 2012). However Uhrf1, which recruits Dnmt1 
onto hemimethylated DNA, can bind hemi- and fully hydroxymethylated CpG 
sites with similar affinity  (Sharif, Muto et al. 2007; Frauer, Hoffmann et al. 2011). 
Therefore, it should be investigated whether a Uhrf1-mediated mechanism 
maintains hemihydroxymethylated sites over cell divisions in vivo. 
A second proposed role for 5hmC  is an intermediate in active demethylation 
events, such as the reprogramming of methylome during embryogenesis, where 
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global methylation patterns are erased and a wave of de novo methylation 
follows (Mayer, Niveleau et al. 2000; Hajkova, Erhardt et al. 2002; Chen, Ueda et 
al. 2003; Hackett, Zylicz et al. 2012). This way a pluripotent state can be 
established in the zygote and then again in developing primordial germ cells 
(Reik, Dean et al. 2001). Within hours of fertilization, the male genome is stripped 
of methylation at a faster rate than cell division (Oswald, Engemann et al. 2000). 
Several groups have proposed that this process involves active demethylation 
mechanisms via DNA glycosylases, other putative DNA decarboxylases (Wu and 
Zhang 2010; Cortellino, Xu et al. 2011; He, Li et al. 2011; Inoue and Zhang 2011; 
Maiti and Drohat 2011; Hashimoto, Hong et al. 2012), or deaminases that can 
convert 5hmC into 5-hyroxymethyluracil (5hmU) in combination with base 
excision repair (BER) mechanisms (Zhu 2009; Branco, Ficz et al. 2012; Hackett, 
Zylicz et al. 2012; Morera, Grin et al. 2012). These hypotheses have drawn 
special attention after the discoveries that the demethylation of paternal genome 
follows a wave of hydroxymethylation (Iqbal, Jin et al. 2011; Wossidlo, Nakamura 
et al. 2011); and that 5hmC can be further oxidized to 5-formylcytosine (5fC) and 
then to 5-carboxycytosine (5caC) in vitro (Ito, Shen et al. 2011). However, 5fC 
and 5caC was not detected during zygote development (Inoue, Shen et al. 2011). 
Despite the recent accumulation of data, it is still not fully understood whether an 
active demethylation event, that involves oxidization of 5hmC into 5fC and 5caC 
followed by TDG-mediated base excision, takes place in vivo. (Cortellino, Xu et 
al. 2011; He, Li et al. 2011; Maiti and Drohat 2011; Hashimoto, Hong et al. 2012; 
Morera, Grin et al. 2012).
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Finally, the accumulation of 5hmC in the brain and the differential distribution of 
5hmC on different loci between brain areas strongly support a stable epigenetic 
role for 5hmC (Globisch, Münzel et al. 2010; Nestor, Ottaviano et al. 2011; Song, 
Szulwach et al. 2011; Szulwach, Li et al. 2011). In this scenario 5hmC can (1) 
evict proteins that bind methylated sequences; (2) recruit novel factors that avidly 
bind hydroxymethylated sequences; and/or (3) change DNA structure within 
chromatin. 
I.XII. Intermission: a retrospective methodological evaluation
! The addition of a third dimension to the cytosine modification status 
necessitated the re-evaluation of the traditional methods to analyze genomic 
methylation, since they operate in binary mode, where 5hmC, 5fC and 5caC 
have been detected in either C or 5mC population.  
•   Quantification methods 
The traditional method to quantify global levels of methylation is nearest-neighbor 
analysis (Ramsahoye and Mills 2002), where a restriction enzyme creates a 
“sticky end” on DNA where it is labeled. The labeled nucleotides on these ends 
are separated by  chromatography. A second method is use of methylation-
sensitive restriction enzymes that can cleave DNA only if the target site is 
unmodifed (Pells, Moore et al. 2006). However both methods limit the analysis to 
a 4-6 bp site covering small part of the genome; they are biased for the 
dinucleotide context, the resistance of 5hmC, 5fC and 5caC  is unknown and the 
former is also strongly dependent on the chromatography conditions 
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(Ramsahoye and Mills 2002; Ito, Shen et al. 2011). Today, the most sensitive and 
robust techniques to quantify  modified nucleosides are high-performance liquid 
chromatography, mass spectrometry and nanopore amperometry (Pomerantz, 
McCloskey et al. 1990; Quinlivan and Gregory 2008; Clarke, Wu et al. 2009). 
•  Mapping methods 
To analyze methylation status of specific loci scientists originally used MBDs to 
enrich methylated DNA (Cross, Chariton et al. 1994; Rauch and Pfeifer 2005; 
Rauch, Li et al. 2006). However each MBD exhibits a different binding pattern, 
making this method inherently biased. For instance, in one study the genomic 
localization of MeCP2 was shown to track with DNA methylation pattern (Skene, 
Illingworth et al. 2010), which was evaluated using the MBD of the same protein 
(Illingworth, Kerr et al. 2008). Furthermore, initially only a few selected loci were 
analyzed (Meissner, Mikkelsen et al. 2008; Irizarry, Ladd-Acosta et al. 2009) until 
genome-wide sequencing methods were developed. Currently methylated DNA 
immunoprecipitation (MeDIP-Seq) is widely  used in combination with high-
throughput sequencing (Weber, Davies et al. 2005), while antibodies developed 
for hydroxymethylated DNA immunoprecipitation (hMeDIP-Seq) show high 
background, especially with repetitive sequences. (Jin, Kadam et al. 2010; Ficz, 
Branco et al. 2011; Williams, Christensen et al. 2011; Xu, Wu et al. 2011). 
Therefore, antibodies were developed against cytosine-5-methylenesulphonate, 
product of bisulfite treatment of 5hmC (Ko, Huang et al. 2010; Pastor, Pape et al. 
2011). 
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In a recent chemical labeling technique, T4 bacteriophage β-glucosyltransferase 
(βGT) transfers an azide-containing glucose moiety onto the hydroxyl group of 
5hmC. The azide group  then chemically incorporates a biotin group that can be 
used for detection, affinity enrichment or sequencing (Song, Szulwach et al. 
2011; Robertson, Dahl et al. 2012). Glucosylation reaction alone can also be 
used for modification-resistant restriction enzymes that are blocked by 
glucosylation. Finally, a restriction enzyme that has been cloned almost two 
decades ago, cleaves DNA at hydroxymethylcytosine independent of sequence, 
and its activity is also blocked by glucosylation (Janosi, Yonemitsu et al. 1994).
•   Base-resolution sequencing methods 
In BS-Seq, DNA is treated with bisulfite, which converts all unmodified Cs into 
uracils, and the comparison of the treated sequence to the original sequence 
reveals 5mCs (Frommer, McDonald et al. 1992). Soon after the finding that 
5hmC behaves like 5mC in BS-Seq whereas 5fC  and 5caC behave like 
unmodified C; new techniques were invented to incorporate 5hmC into BS-Seq 
via an Tet-mediated or chemical oxidation step (Huang, Pastor et al. 2010; Booth, 
Branco et al. 2012; Yu, Hon et al. 2012). In a single-molecule real-time 
sequencing, kinetic signatures of a mutated DNA polymerase are monitored 
during incorporation of fluorescent nucleotides (Flusberg, Webster et al. 2010).
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I.XIII. Tets: enzymes in the making of 5hmC
! The methyl group of 5mC can be oxidized to 5hmC in vitro and in cell 
cultures by any of the three recently identified members of the Ten-eleven 
translocation (Tet) family of proteins, which belong to the superfamily of 2-
oxoglutarate- and iron-dependent dioxygenases (Fig 1.4) (Iyer, Tahiliani et al. 
2009; Tahiliani, Koh et al. 2009; Ito, D'Alessio et al. 2010). TET1 and TET2 are 
both implicated in cancer (Ono, Taki et al. 2002; Lorsbach, Moore et al. 2003; 
Burmeister, Meyer et al. 2009; Abdel-Wahab, Mullally  et al. 2009; Ko, Huang et 
al. 2010); and so are enzymes that cause inhibition of Tets (Xu, Yang et al. 2011). 
They are also the key enzymes responsible for the presence of 5hmC  in ES 
cells, as opposed to Tet3, which is highly expressed in terminally differentiated 
tissues (Ito, D'Alessio et al. 2010; Koh, Yabuuchi et al. 2011). Although these 
data suggest a role for Tet1 and Tet 2 in ES cell pluripotency and oncogenic 
transformation; their roles in ES cell self-renewal and maintenance of pluripotent 
state has been contradictory  (Ito, D'Alessio et al. 2010; Dawlaty, Ganz et al. 
2011; Koh, Yabuuchi et al. 2011; Williams, Christensen et al. 2011; Freudenberg, 
Ghosh et al. 2012).
 All Tet enzymes can oxidize 5hmC further into 5fC  and 5caC  in vitro (Inoue, 
Shen et al. 2011). Evidence suggests that Tet3 mediates the demethylation of 
paternal genome (Iqbal, Jin et al. 2011; Wossidlo, Nakamura et al. 2011), 
whereas a recent report proposes a regulatory role for Tet1 in the expression of a 
subset of meiotic genes during generation of oocytes (Yamaguchi, Hong et al. 
2012). The increased methylation at many CGIs caused by  depletion of Tet1 (Xu, 
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Wu et al. 2011) and hypomethylation in patients with TET2 mutations (Ko, Huang 
et al. 2010) also support a role for Tets in demethylation pathways, yet more 
research needs to be done to establish a coherent model. Although active 
demethylation has also been advocated in the brain, this hypothesis was based 
on cultured neurons that over-expressed Tet1 (Guo, Su et al. 2011). In addition, 
intermediate products, 5fC, 5caC and 5hmU were not detected in terminally 
differentiated tissues (Globisch, Münzel et al. 2010; Pfaffeneder, Hackner et al. 
2011). 
In ES cells Tet1 also colocalizes with both active (Pastor, Pape et al. 2011) and 
repressive histone marks, and also bivalent sites, that carry with both repressive 
and activating marks (Wu, D'Alessio et al. 2011; Xu, Wu et al. 2011), with a 
strong preference for unmodified CGIs within promoter regions and less within 
gene bodies (Williams, Christensen et al. 2011; Wu, D'Alessio et al. 2011). This 
suggests that it may also be functioning as a transcriptional modulator via its 
CXXC domain (Zhang, Zhang et al. 2010), which is indeed dispensable for its 
catalytic activity in vivo (Frauer, Rottach et al. 2011). 
I.IV. 5hmC in the brain
! The existing data can partly describe active demethylation events during 
development, yet they are still not sufficient to explain the accumulation of 5hmC 
in terminally differentiated cells. Although an active demethylation is advocated in 
the brain, this hypothesis was based on cultured neurons that overexpressed 
Tet1 (Guo, Su et al. 2011). In addition, intermediate products, 5fC, 5caC  and 
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5hmU were not detected in terminally differentiated tissues (Globisch, Münzel et 
al. 2010; Pfaffeneder, Hackner et al. 2011). On the other hand, the location of 
5hmC in the genome is significantly different in the brain, and most differentially 
hydroxymethylated regions (DhMRs) between different neuroanatomical regions 
are stable throughout life (Szulwach, Li et al. 2011; Chen, Dzitoyeva et al. 2012; 
Wang, Pan et al. 2012). To gain more insight, our group  recently mapped 5mC 
and 5hmC in specific cell types in the brain, taking advantage of bacTRAP mice 
(Heintz 2000; Heiman, Schaefer et al. 2008), that express a ribosomal protein, 
L10A, tagged with enhanced green fluorescent protein (eGFP) in cell bodies (Fig 
1.5.A) and nucleoli (Fig 1.5.B) of specific neuronal subpopulations. Having 
eGFP-tagged ribosomes allowed both the enrichment of mRNA and the isolation 
of genomes from specific cell types (Mellen, Ayata et al. 2012). In general, the 
distribution of 5hmC across the genome in specific types of neurons and glia was 
in agreement with previous studies of brain tissue (Song, Szulwach et al. 2011; 
Szulwach, Li et al. 2011): 5hmC was preferentially enriched over the entire 
transcription unit of expressed genes, and depleted from both the TSS and 
intergenic regions. In highly expressed genes 5mC was depleted over the gene 
bodies, whereas the enrichment of 5hmC varied between cell types. The patterns 
of 5hmC and 5mC were inversely  correlated. These findings by  our group, a 
recent study where 5hmC was found enriched in gene bodies of synaptic genes 
(Khare, Pai et al. 2012), and the detection of DhMRs, support that 5hmC  is a 
stable epigenetic mark in the brain that is utilized in a clearly different manner for 
neural functions.
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I.V. Epilogue: the search for 5hmC-binding proteins
! 5hmC revealing itself as a stable and activating mark in the brain, raises 
immediate questions: (1) by  which upstream events is this epigenetic code 
written at specific locations in the brain that differ from pluripotent cell states; and 
(2) by which downstream implications is it interpreted as a stable and activating 
mark. The aim of this study is to address the second question by trying to unveil 
nuclear factors that recognize the 5hmC mark in the brain. Factors that bind to 
methylated DNA, have elucidated the main mechanisms that convert 5mC into a 
repressive mark. Two 5hmC-binding proteins have been previously reported: 
First, Frauer et al. showed that Uhrf1 recognizes hydroxymethylated CpGs 
(5hmCpGs) (Frauer, Hoffmann et al. 2011). Although this finding was informative 
for the maintenance of 5hmC, it did not provide any  insight of its interpretation as 
an epigenetic mark. Later, Yildirim et al. demonstrated that Tet1 and MBD3 
colocalize in ES cells (Yildirim, Li et al. 2011). This study proposed an alternative 
control of gene expression of bivalent genes in pluripotent cells, by the repressor 
MBD3 and activator Brg1. Yet this group  also could not establish a direct 
functional link between 5hmC  and active chromatin states in postmitotic cells. 
The study we present here, attempts to solve this conundrum by identification 
and functional characterization of brain-specific proteins that recognize 5hmC. 
Thus, we hope to elucidate mechanisms that can read the 5hmC  code and 
translate it into an activation mark in the brain.
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Chapter II.
MeCP2 binds to 5hmC at CpA dinucleotides enriched 
in the bodies of the active genes in euchromatin
II.I. MeCP2 is an abundant 5hmC binding protein
! To identify the factors that may be responsible for decoding 5hmC in the 
brain, nuclear extracts prepared from rodent brain (Klose and Bird 2004) were 
incubated with magnetic beads coated with DNA containing unmodified C, 5mC 
or 5hmC in the presence of excess non-specific DNA competitor. After the beads 
were isolated, proteins captured on the beads were eluted and separated on 
SDS PAGE.  Silver staining of this gel revealed a band of ~70 kDa enriched with 
both 5mC and 5hmC, but not with C (Fig 2.1.A). This band was excised from a 
preparative gel of this type, analyzed by mass spectroscopy and identified as 
MeCP2 in a peptide database search with ~50% sequence coverage (Fig 2.1.B). 
Since it is possible that novel low-abundance 5hmC binding proteins might be 
obscured by the abundant MeCP2, we repeated this experiment in the absence 
of MeCP2. Nuclear extracts were prepared from Mecp2-KO animals using beads 
coated with DNA containing C  or 5hmC. Upon visualization by Coomassie or 
more sensitive Silver stain, we did not detect any 5hmC-specific bands in the 
eluates from KO animals (data not shown). As an alternative detection, we 
transferred the electrophoresed eluates from wild type (WT) and KO onto a 
charged membrane and analyzed it by Southwestern blotting method 
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(Campoy, Meehan et al. 1995). Thus, membrane bound re-natured proteins were 
probed with DNA end-labeled with 32P isotope containing either 5mC or 5hmC, 
revealing a protein of the correct molecular weight that can bind both 5mC and 
5hmC containing DNA probes from WT animals, and that is not present in 
samples prepared from KO animals (Fig 2.1.C). To our surprise, no other 
abundant protein with high specificity for 5hmC  DNA was revealed in these 
studies, even in the absence of MeCP2.
 
II.II. Recombinant MeCP2 specifically binds to 5mC and 5hmC
!  To test the binding of MeCP2 to 5hmC directly, a His-tagged N-terminal 
fragment (NT) of human MeCP2 containing the MBD (residues 1-205) was 
produced in E. coli and purified using Nickel-nitrilotriacetic acid (Ni-NTA) resin 
(Fig 2.2.A). Probes with C, 5mC  or 5hmC nucleotides were prepared (Fig 2.2.B) 
and used in electrophoretic mobility  shift assays (EMSA) to measure binding. At 
all concentrations tested, the MeCP2 NT failed to bind the C-containing probe, 
while avidly binding both the 5mC and 5hmC probes (Fig 2.2.C).We also have 
purified the minimal MBD (residues 77-167) of MeCP2 and  confirmed that MBD 
was sufficient for this binding (Fig 2.2.D). As an additional control, EMSAs also 
were performed using probes reacted with T-4 phage β-glucosyltransferase 
(βGT), which adds a glucose from uridine diphosphoglucose (UDP-glucose) 
specifically to the -OH group of 5hmC without affecting 5mC and C nucleotides 
(Szwagierczak, Bultmann et al. 2010). The binding of MeCP2 NT to the 
glucosylated 5hmC probe was blocked due to glucosylation of 5hmC residues 
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and retained as 5mC, which is refractive to glucosylation (Fig 2.2.E). MeCP2 
binding to 5hmC  was not sequence specific since the binding properties of 
MeCP2 to a variety of probes selected from the mouse genome did not vary 
significantly. 
We set up to examine the modification-specific interaction of other MBD family 
proteins. A schematic view of the recombinant fragments of MBDs is shown in 
Fig 2.3.A. We purified His-tagged MBDs 1 through 4 using a column prepared 
with Ni-NTA (Fig 2.3.B) (Janknecht, de Martynoff et al. 1991). In contrast MBD1, 
2 and 4 all bound strongly to 5mC containing DNA, and did show specificity to 
5hmC containing probes (Fig 2.3.C). As previously reported (Yildirim, Li et al. 
2011), binding of MBD3 was observed to both 5mC and 5hmC DNAs, and the 
mobility  of the MBD3/5hmC complex was slightly  retarded relative to the 
MBD3/5mC complex. MBD3 binding to both 5mC and 5hmC was much weaker, 
requiring amounts that are two orders of magnitude higher than the other MBD 
proteins, and its binding to 5hmC DNA was sensitive to glucosylation. A weak, 
5hmC-specific and βGT-sensitive was also observed with MBD4. 
We verified these observations by competition assays: in the absence of a 
nonspecific competitor, unlabeled, or “cold” probes containing 5mC  and 5hmC 
can compete out the binding of MeCP2 to radioactively  labeled, or “hot”, 5mC-
containing DNA probe with the same efficiency (Fig 2.4.A). This effect is much 
less pronounced for C. On the contrary, “cold” 5mC-containing probe could 
compete out the binding of MBD1 and 2 to radioactive probe containing 5mC, 
much more efficiently than “cold” probes containing C or 5hmC (Fig 2.4.B and C). 
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II.III. RTT mutation R133C preferentially inhibits binding to 5hmC
! If binding of MeCP2 to 5hmC is critical for its role in the regulation of 
neuronal nuclear function and gene expression, then it is possible that a subset 
of the MeCP2 mutations that cause RTT disrupt 5hmC  binding without strongly 
impacting 5mC interaction. To determine if this is the case, binding of MeCP2 
MBDs (aa 1-205) carrying a variety of previously  characterized RTT mutations 
were assayed (Kudo, Nomura et al. 2003). Here we focused on residues that (1) 
do not alter the MeCP2 binding and nuclear localization significantly, (2) located 
in the DNA binding pocket, and (3) show atypical or mild phenotypes in RTT 
database (http://mecp2.chw.edu.au/mecp2/). We also included a newly identified 
mutation S134F (Lima, Brunoni et al. 2009). To represent two extreme cases of 
DNA binding activity three mutations were selected: D121G, that abolishes 5mC 
binding, and L100V and A140V, that donʼt directly interact with DNA, maintain 
wild type affinity to 5mC and show milder phenotypes (Orrico, Lam et al. 2000; 
Couvert, Bienvenu et al. 2001; Jentarra, Olfers et al. 2010). The rest of the 
disease-causing mutations in the MBD were chosen because they showed no or 
little disruption of nuclear localization or 5mC-binding. We produced these in E. 
coli and purified as previously described (Fig 2.5.A). Although the general effect 
of mutations in this series was to inhibit binding to both 5mC and 5hmC DNAs to 
a similar degree or to remain unchanged, we observed a pronounced decrease 
in the interaction with 5hmC relative to 5mC  DNA with the MeCP2 MBD carrying 
the R133C substitution (Fig 2.5.B). 
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Since R133C and R133H are mutations at the same location, yet give different 
affinities for modified probes, next we wondered if it would be possible to 
“improve” this differential binding by designing artificial mutants that bound 5mC 
as efficiently as WT and showed nonspecific binding to both 5hmC and C. Hence 
we designed R133 mutants by  replacing the positively charged R residue with 
another positively charged residue of smaller size (R133K), a negatively charged 
residue (R133E), a hydrophobic residue (R133M) and a hydrophilic residue 
(R133S). The binding of most of these mutants to 5mC was not affected yet their 
binding to 5hmC was reduced (Fig 2.6.A). This discrepancy  was pronounced with 
residues that contain a negatively charged atom such as sulfur (in R133C and 
R133M) and oxygen (in R133E and R133S). We hypothesize that this is due to 
their vicinity  to the oxygen of the hydroxyl group  of 5hmC. The binding of mutants 
containing R133H and R133K to both 5mC and 5hmC was strongly reduced (Fig 
2.6.B). To test whether this effect is also conserved in the full-length (FL) 
proteins, we purified FL WT MeCP2, the RTT mutation R133C and two of the 
artificial mutants R133E and R133S. Since the FL protein cannot be separated in 
EMSA gel, we separated these proteins on SDS page (Fig 2.6.C), transferred 
them onto a charged membrane, and analyzed it by Southwestern method as 
before. The membrane-bound re-natured proteins were probed with radioactive 
DNA probes containing either 5mC  or 5hmC  (Fig 2.6.D). We normalized the 
signal of both membranes to the signal from WT NT of MeCP2 and detected no 
binding activity of R133C and R133E mutants to 5hmC containing DNA, whereas 
R133S showed weak binding to 5hmC. 
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II.IV. Binding of MBD proteins to C, 5mC and 5hmC
! To investigate these findings in more detail, and to provide independent 
data supporting the conclusions of the EMSA assays presented above, surface 
plasmon resonance (SPR) assays were used to measure the binding of full 
length MeCP2, the MeCP2 MBD, other MBD proteins, and the MeCP2 carrying 
R133C mutation to 5hmC, 5mC and C containing DNA (Malmqvist 1999). 5ʼ-
biotinylated DNA probes prepared using C, 5mC or 5hmC nucleotides were 
immobilized on parallel flow cells (Fc) of a streptavidin-coated sensor chip to a 
level of 500 (±25) resonance units (RU). Several dilutions of purified recombinant 
proteins were then introduced to each Fc in parallel and the change in SPR 
response over time was recorded. By visual inspection of overlay plots of such 
response by MeCP2 NT and MBD2, the specific binding of MeCP2 to both 5mC 
and 5hmC and the specific binding of MBD2 to 5mC were readily  observed (Fig.
2.7.A). Next, we plotted the SPR response of these proteins at saturation against 
the corresponding protein concentration, to represent the steady-state binding 
(Fig 2.7.B). As predicted, MeCP2 NT showed specific binding to both 5mC and 
5hmC containing DNA that was strongly dependent on protein concentration, 
whereas binding to C-containing DNA plateaued at very low protein 
concentrations, consistent with nonspecific binding. In contrast, MBD2 bound 
strongly to 5mC-containing DNA and did not bind to DNA containing C or 5hmC. 
We then expanded these assays to other MBDs, FL MeCP2 and FL MeCP2 
containing the R133C point mutation. In SPR experiments MBD3 did not show 
specific binding to any  probe (data not shown). As expected, MBD1 and 4 
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showed specific binding only to 5mC  DNA (Fig 2.8.A). As predicted, the binding 
characteristics of FL MeCP2 was as NT (Fig 2.8.A), consistent with the pull down 
experiments, the Southwestern results and the EMSA data presented above. 
Interestingly, binding of the MeCP2 R133C mutant to 5hmC was very strongly 
depressed relative to binding to 5mC  DNA, although a small effect on overall 
binding to 5mC was evident. To further assess these results, the Bmax of 
proteins binding to each probe were calculated from steady-state binding curves 
to generate quantitative binding data for each protein (Fig 2.8.B). No significant 
difference was observed in the measured Bmax of MeCP2 binding to 5mC and 
5hmC. The most interesting and unexpected outcome of these calculations is 
that the R133C MeCP2 mutant retained most of its 5mC  binding capability (Bmax 
= 76% of WT, p=0.77) despite loss of specific binding to 5hmC (Bmax = 25% of 
WT, p  = 0.0029). The fact that this single substitution in the MeCP2 MBD can 
strongly and preferentially  impact the substrate binding properties of MeCP2 is 
important because identification of MeCP2 mutations that retain WT 5mC 
binding, in the R133C variant yet retain severely  diminished 5hmC binding can 
provide an important avenue for assessing the role of MeCP2 binding to 5hmC in 
the pathophysiology of RTT. Furthermore, these data demonstrate that small 
changes in the structure of MeCP2 may influence its relative binding properties to 
5mC and 5hmC, raising the interesting possibility that the posttranslational 
modifications to MeCP2 that have been shown to occur in response to a variety 
of stimuli (Chen, Chang et al. 2003; Tao, Hu et al. 2009; Rutlin and Nelson 2011) 
could alter its substrate specificity and downstream functions.  
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II.V. MeCP2 binds to 5hmC and 5mC in CpA context 
! The identification of MeCP2 as a major 5hmC binding protein in rodent 
brain is surprising given previous in vitro studies reporting that it binds 5mC-
containing DNA much more avidly than 5hmC-containing DNA (Valinluck, Tsai et 
al. 2004; Bostick, Kim et al. 2007). The most notable difference between previous 
studies and ours was the preparation of the DNA: Other studies utilized probes 
prepared by dimerization of chemically  synthesized short oligonucleotides with a 
single modification in CpG context, where we amplified probes from a native 
genomic sequence using dCTP, d5mTP or d5hmTP. The resulting probe is a 120 
bp  probe that is densely  modified (as in some regions of the genome) where the 
modified residues can exist in every possible dinucleotide context. To address 
this issue directly, we prepared probes that were modified on a single C  in all 
dinucleotide and trinucleotide contexts. In order not to compromise the DNA 
binding of MeCP2 we used long, 75 bp, probes rich in A/T bases near the 
modification. To our surprise, MeCP2 failed to bind to the 5hmCpG dinucleotide, 
in agreement with the earlier studies, yet its binding was nearly  as strong for the 
5mCAC trinucleotide as well as 5hmCAC (Fig 2.9.A). It bound with similar affinity 
to both 5mCAT and 5hmCAT trinucleotides. We observed considerably  low 
binding with 5mCGA and 5mCAA trinucleotides, but binding was abolished in 
5hmCGA and 5hmCAA. MeCP2 also did not bind any  CpC or CpT nucleotides or 
any of the hybrid CpGs, where the modification status of the two strands differed 
(data not shown). In addition, R133C mutant conserved the binding to 5mCpG 
and 5mCpA but lost its affinity to hydroxymethylated CpAs (5hmCpAs), indicating
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that R133 residue is crucial for 5hmC recognition but not for the recognition of 
the subsequent pyrimidine (Fig 2.9.B). As expected, both MBD1 and MBD2 did 
not bind either DNA containing C or 5hmC, or 5mC in CpA context. MBD2 bound 
DNA with a single 5mCpG strongly; however, MBD1 showed low binding. The 
identity of the fourth nucleotide did not affect binding (data not shown).
We next performed pulldowns in nuclear extract from rodent brain using DNA 
baits carrying a single modification in CpA or CpG context, enriched MeCP2 in 
DNA-bound eluates by immunoprecipitation and confirmed our binding data by 
Western blot of the euates using an antibody against MeCP2 (Fig 2.9.D, left). 
Interestingly, when we used an anti-phosphoserine antibody, we saw a band 
specific for proteins eluted from the methylated DNA bait (Fig 2.9.D, right). 
However, we cannot currently conclude that the source of this band is MeCP2.
To analyze this binding more in detail, we conducted a new generation SPR 
analysis (Abdiche, Lindquist et al. 2011), where we immobilized biotinylated DNA 
probes containing a single CGCT, 5mCGCT, 5hmCGCT, 5mCACT and 
5hmCACT on a neutravidin-coated array to a level of 550 (±40) RU and 
measured the response by several dilutions of WT MeCP2 NT and R133C in 
parallel. The equilibrium analysis was performed using ProteOn Software. As 
expected, MeCP2 showed specific binding to 5mCpG, 5mCpA and 5hmCpA (Fig 
2.10.A). Interestingly, the binding of R133C mutant to 5mCpG was at WT levels, 
yet its binding to 5mCpA was reduced. We observed more significant effect on its 
5hmCpA binding. To verify our observations, we extracted Bmax values using 
ProteOn Software for each protein and DNA modification (Fig 2.10.B). 
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These results showed that MeCP2 preferentially  binds a methylated site within 
the context Cp(A/G)p(T/C) > Cp(A/G)p(A/G), whereas hydroxymethylated target 
sites are within the context CpAp(T/C). Since non-CpG modification, primarily 
CpA(C), makes up 20-25% of the modified cytosines (Laurent, Wong et al. 2010), 
it is likely that a substantial population of MeCP2 is bound on modified CpAs in 
vivo. Additionally, modified non-CpG sites are are preceded by a TA dinucleotide 
upstream and followed by an A or T (Lister, Pelizzola et al. 2009). Such pattern 
may be stabilizing the binding by MeCP2 which possesses two consensus A/T-
hook motifs of MeCP2 (Ho, McNae et al. 2008). Given that modified CpAs are 
concentrated in the bodies of active genes and strongly correlate with gene 
expression (Lister, Pelizzola et al. 2009), and that genes that are highly 
expressed lack methylation but are largely hydroxymethylated (Mellen, Ayata et 
al. 2012), one can expect that such genes have high levels of hydroxymethylated 
CpAs. Although single nucleotide data is not yet available, asymmetrical 
hydroxymethylation is observed at high levels throughout the transcription unit of 
active genes, and such regions contain extensive amounts of modified non-CpG 
dinucleotides (Ficz, Branco et al. 2011). If a considerable fraction of MeCP2 
target sites are hydroxymethylated CpAs enriched in the bodies of active genes 
within euchromatin, we hypothesize that these sites may be bound in vivo by  the 
previously identified subpopulation of MeCP2, that is loosely bound and 
associated with active states of genes and chromatin (Thambirajah, Ng et al. 
2011).
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II.VI. MeCP2 facilitates chromatin accessibility around 5hmC
! Given that MeCP2 can not only tightly bind densely packed regions of 
silent chromatin, enriched in 5mC, but also is loosely associated with accessible 
regions of chromatin, which are where active genes, 5hmC and modified CpAs 
are extensively found, we next were interested in assessing its potential role in 
global regulation of chromatin accessibility. To do so, cerebellar nuclei were 
isolated from five-week-old WT and KO male mice (Guy, Hendrich et al. 2001). 
For each sample, a time course of MNase digestion was performed, and the 
release of 5hmC- and 5mC-enriched DNA fragments prepared by Southern 
blotting and assayed with antibodies against 5mC and 5hmC (Fig 2.11.A). To 
quantitate and normalize the data from different digestions, the signal from 
quadrant 1 (Q1) to Q4 in each lane was measured in four independent cohorts of 
WT and KO mice, and the data quantified as the percentage of total signal in 
each time of digestion (Fig 2.11.B). We denoted the signal present in the Q1 
fraction as nuclease-resistant fraction and plotted that against the early digestion 
times (Fig 2.11.C). Two interesting results were obtained: First, we observed that 
5hmC-enriched DNA is released readily from chromatin by MNase digestion, 
whereas 5mC-containing chromatin is significantly more resistant to digestion. 
This is consistent with the analysis of individual genes, and confirms previous 
studies demonstrating the 5mC enriched DNA is present in MNase-resistant 
compact structures (Karymov, Tomschik et al. 2001). Second, in Mecp2-null mice 
a significant, small delay  in digestion of 5hmC-containing DNA was observed, 
whereas no reproducible difference in the sensitivity of 5mC-containing DNA to 
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MNase was evident. These data demonstrate that MeCP2 regulates the 
accessibility of 5hmC-containing DNA to MNase, supporting a model in which 
MeCP2 binding to 5hmC within highly expressed genes may facilitate 
transcription through its effects on chromatin organization.  
II.VII. Discussion
! The data presented here identify  a novel role for MeCP2 in the regulation 
of chromatin structure in support of a new model for the organization of 
accessible chromatin states around expressed genes that is specific to the 
vertebrate nervous system, in addition to the traditional repressive and silencing 
functions it elicits upon its binding to 5mCpG dinucleotides (Guy, Hendrich et al. 
2001). Based on the previous literature and our findings, we propose that binding 
of 5hmCpA by MeCP2 plays a central role in the fine tuning of chromatin states 
that facilitate expression of neural genes. The mechanism by which MeCP2 
binding to 5hmCpA regulates chromatin accessibility is evidently different from its 
repressive role within heterochromatin regions enriched in 5mC and remains to 
be deciphered. However this model, based on our binding data, is substantiated 
by the fact that both 5hmC  and MeCP2 are at least an order of magnitude more 
abundant in the nervous system than in the periphery (Kriaucionis and Heintz 
2009; Skene, Illingworth et al. 2010); that both modified CpA dinucleotides and 
5hmC are abundant on bodies of active neural genes and euchromatin; that 
these regions are depleted of 5mC (Lister, Pelizzola et al. 2009; Mellen, Ayata et 
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al. 2012); and that MeCP2 has a yet uncharacterized association with accessible 
chromatin states (Thambirajah, Ng et al. 2011). 
•  5hmCpA, a new epigenetic code in the brain
The accumulation of modified CpA throughout the transcription unit of active 
genes (Lister, Pelizzola et al. 2009; Ficz, Branco et al. 2011), combined with the 
signature depletion of 5mC and accumulation of 5hmC  throughout bodies of 
highly expressed genes (Mellen, Ayata et al. 2012), imply a new depiction of 
epigenetic information in the form of 5hmCpA in correlation with gene expression. 
This differs significantly from the traditional epigenetic language, where 5mCpGs 
compact chromatin into repressive states via MBD and other 5mC-binding 
proteins (Guy, Hendrich et al. 2001; Yildirim, Li et al. 2011). Since CpA 
modification is inherently  “asymmetric”, it is destined to be lost over cell divisions. 
Hence in post-mitotic cells, de novo mechanisms are necessary to establish such 
code that potentially define cell identity  and function. This is crucial for a complex 
network, like the brain, where each cell fulfills a slightly  or fundamentally different 
function from its sister cell. Indeed, non-CpG modification of transcription units of 
highly expressed neuronal genes has been previously  reported (Backdahl, 
Herberth et al. 2009; Cortese, Lewin et al. 2011). It is likely that neuronal genes 
can be methylated at CpA dinucleotides by Dnmt3a in an activity-dependent 
manner; given its neuron-specific euchromatic localization (Wu, Coskun et al. 
2010); its ability to methylate CpAs in vivo (Mund, Musch et al. 2004); and its 
activity-dependent regulation in neurons (Feng, Chang et al. 2005; Miller and 
Sweatt 2007; Nguyen, Meletis et al. 2007; LaPlant, Vialou et al. 2010). Moreover, 
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the de novo DNA methyltransferase, Dnmt3b, is not detected in postmitotic tissue 
(Okano, Bell et al. 1999). Although not much is known about Tet3, we suspect 
that its functions may encompass the hydroxylation of 5mCpAs, since all Tet 
enzymes can hydroxylate methylated CpAs in vitro (Tahiliani, M, personal 
communication); Tet3 is highly expressed in the brain (Szwagierczak, Bultmann 
et al. 2010); and in the absence of Tet1 and Tet2, asymmetric non-CpG 
hydroxymethylation increases (Ficz, Branco et al. 2011). Together these data 
suggest that Dnmt3 and Tet3, or other putative enzymes, may be generating high 
amounts of 5hmCpA. In the brain, both 5hmC and modified CpAs share a similar 
pattern: both are depleted in TSS, but enriched the bodies of highly expressed 
genes within euchromatin (Lister, Pelizzola et al. 2009; Mellen, Ayata et al. 2012), 
therefore we expect that a large proportion of these modified CpAs to be 
hydroxymethylated. This is strongly supported by the finding that these genes are 
invariably depleted from 5mC. 
•  MeCP2, the reader of the new language
In this study, we have shown that MeCP2 binds 5hmCpA in vitro. To appreciate 
this binding at the molecular level, we have modified the existing structural 
information (Wakefield, Smith et al. 1999) using Pymol software. The original 
structure (Fig 2.12.A) conveys the hydrophobic stabilization of the methyl group 
of 5mC by  the arginine chain, as well as the ionic interaction between the 
negative oxygen of guanine (G) and the amino group  of arginine (R). When the 
methyl group  is oxidized in 5hmC (Fig 2.12.B), then two highly negative oxygen 
molecules in 5hmC and G make the interaction unfavorable, whereas the 
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replacement of G by adenine (A) restores the ionic balance. The molecular 
representation of a cysteine residue replacing the arginine (R133C) also provides 
mechanistic insight to the preferential inhibition of 5hmC binding of MeCP2. In a 
hypothetical model, where R133C MeCP2 is bound to 5hmCpA (Fig 2.12.D), the 
nucleophilic sulfur of cysteine would be adjacent to the oxygen of 5hmC. That 
would create an energetically unfavorable state and thus binding would not 
occur. On the other hand, in the 5mCpG-bound R133C MeCP2, the oxygen of G 
and the sulfur atom of cysteine are separated where water molecules may be 
accommodated and stabilize 5mCpG in the binding pocket (Fig 2.12.C). Same 
effect can be observed in some of the other R133 mutants we have created, 
where the distance between the oxygen of 5hmC  and an other nucleophilic atom, 
such as sulfur in R133M (Fig 2.13.B) or oxygen in R133E or R133S (Fig 2.13.D 
and E), is too small to be energetically  favored. In the case of R133K and 
R133H, such strong repulsion is not the case and accordingly, the discrepancy 
between 5mC  and 5hmC  binding is smaller. However, the 5mC binding is more 
strongly reduced. This may be due to steric hinderance and/or displacement of 
water molecules that stabilize the binding pocket (Ho, McNae et al. 2008). 
Given our binding data; and that both 5hmC and MeCP2 are at least an order of 
magnitude more abundant in the nervous system than in the periphery 
(Kriaucionis and Heintz 2009; Skene, Illingworth et al. 2010); we hypothesize that 
MeCP2 binding to 5hmCpA is crucial in the decryption of the new neuronal 
epigenetic code, which we proposed earlier. This code is not accessible to other 
MBD proteins, as they neither recognize 5hmC nor modified CpAs. On the other 
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hand, 5hmCpA is likely  to be occupied by MeCP2 in vivo, not only  because 
MeCP2 avidly binds 5hmCpA in vitro, but also because MeCP2 contains two 
consensus A/T-hook motifs (Ho, McNae et al. 2008), that may be stabilized by 
the TA dinucleotide upstream of modified non-CpG and the A/T downstream
(Lister, Pelizzola et al. 2009). This suggests that the interaction interphase of 
MeCP2 with 5hmCpA may be different than stable complexes established around 
5mCpG by binding of MeCP2 or other less abundant MBD family proteins 
(Lopez-Serra, Ballestar et al. 2006), since the target site is proven to be an 
activating mark within accessible chromatin.
In individual cell types, the level and genomic location of 5hmC and 5mC are 
tightly regulated (Szulwach, Li et al. 2011; Mellen, Ayata et al. 2012) and the local 
protein composition associated with them varies (Lopez-Serra, Ballestar et al. 
2006; Clouaire and Stancheva, 2010). Then a delicate balance between 5mC, 
5hmC, MeCP2 and other MBD proteins may explain the fine tuning chromatin 
states that enable elaborate adjustments of gene expression patterns. As a 
result, changes in the function of MeCP2 (Amir, Van den Veyver et al. 1999; Tao, 
Hu et al. 2009; Adkins and Georgel 2011) will disrupt such balance at varying 
severity in each cell type, and the phenotypic consequences will be cell-type and 
circuit specific. In mice, after the neurodevelopment is completed in the 
cerebellum and MeCP2 expression reaches a plateau (Skene, Illingworth et al. 
2010), ~85% of DhMRs within specific tissues are stably maintained (Szulwach, 
Li et al. 2011). Interestingly, these stable DhMRs are not altered in the absence 
of Mecp2, supporting the downstream role of MeCP2 in these regions.  Although 
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the total 5hmC signal increased by <20% in the absence of Mecp2, this change 
was restricted to gene body DhMRs, leading the scientists to propose a gene-
body specific role for MeCP2 (Szulwach, Li et al. 2011). 
•  Bilingual MeCP2 
The exact mechanisms by which 5hmCpA is interpreted by MeCP2 into open 
chromatin states to facilitate gene transcription is still unclear. Binding to 
5hmCpA within euchromatin and active genes, in addition to 5mCpG within 
heterochromatin and silent genes, juxtaposes two contradicting roles for MeCP2. 
Intriguingly, a similar contradiction has been presented in the earlier studies: the 
apparent action of MeCP2, that is more akin to a linker histone coating the whole 
genome (Skene, Illingworth et al. 2010) and the detection of two populations of 
MeCP2 in the brain, one loosely bound in highly accessible chromatin domains 
and the other tightly bound in heterochromatin regions that are rich in 
nucleosomes (Thambirajah, Ng et al. 2011). It is likely  that this latter population of 
MeCP2 can stably associate with nucleosomes participating in methylated 
regions in heterochromatin (Chandler, Guschin et al. 1999). The euchromatic 
MeCP2 population, however, may be occupying expressed genes through its 
binding to 5hmCpA (Fig 2.14.A). Since the 50% of the demand for histone H1 is 
supplied by MeCP2 in the brain (Skene, Illingworth et al. 2010; Ghosh, Horowitz-
Scherer et al. 2010), the regulation of global chromatin state in neurons might as 
well be largely  mediated by the distribution of different populations of MeCP2 
over the neuronal genome. We propose that a population of MeCP2 is loosely 
bound to 5hmCpA within active transcription units and facilitates chromatin 
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accessibility by unknown mechanisms, with other populations still being tightly 
associated with silent chromatin. This model provides a possible explanation for 
the recent demonstration that Mecp2 gene dosage positively correlates with the 
expression of the majority of the genes in the brain (Chahrour, Jung et al. 2008; 
Ben-Shachar, Chahrour et al. 2009). If the distribution of MeCP2 over the whole 
genome fine tunes accessible and silent chromatin states, then a dose-
dependency should be crucial. Indeed, changes in the level or activity of MeCP2 
that disturbs this balance results in alterations of chromatin structure and, 
consequently, gene expression. This has been manifested by the disease 
phenotypes that arise when MeCP2 is overexpressed by only two-fold (Collins, 
Levenson et al. 2004) and when the activity-dependent posttranslational 
modifications of MeCP2 were impaired (Cohen, Gabel et al. 2011; Li, Zhong et al. 
2011). An interesting strategy to observe the consequences of such balance 
shifts would be to manipulate 5hmC levels in vivo and observe how MeCP 
populations dislocate and how this is reflected in the phenotype.
•  R133C, lost in translation
Our understanding of the pathophysiology of RTT must now encompass both the 
role of MeCP2 binding to 5mC in the silent chromatin states (Chahrour, Jung et 
al. 2008), and present results supporting a model in which MeCP2 binds to 5hmC 
within active transcription units (Fig 2.14.A). Our finding suggests that disease-
causing mutation R133C displaces euchromatic MeCP2 and shifts the balance 
towards heterochromatin-associated MeCP2 (Fig 2.14.B). Because of the 
observations that the distribution of 5hmC, 5mC and their relationship to gene 
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expression vary  depending on the cell type, the change in the distribution of 
MeCP2 population upon R133C mutation may present an important avenue 
toward understanding the biochemical mechanisms causing qualitative and 
quantitative aspects of RTT phenotype. It is well documented that patients 
carrying the R133C mutation have a milder form of RTT that is characterized by 
delayed-onset regression, with improved speech and motor skills (Bebbington, 
Anderson et al. 2008). However, for many other characteristics, including 
breathing abnormalities, sleep problems, mood disturbances, and epilepsy 
prevalence, no significant differences are evident between patients bearing 
R133C or other mutations (Bebbington, Anderson et al. 2008). 
Although some studies presented data supporting that R133C mutation impairs 
the binding of 5mC by MeCP2 (Ballestar, Yusufzai et al. 2000; Ballestar and 
Wolffe 2001), our results and other studies contradicted this idea, showing that 
this mutation shows binding characteristics that are closer to WT than other 
mutations in the MBD (Kudo, Nomura et al. 2003; Ghosh, Horowitz-Scherer et al. 
2008; Kumar, Kamboj et al. 2008; Mund, Musch, et al. 2004; Fan, Nikitina, et al. 
2005). Although it is possible that a mild impairment in 5mC binding might be 
important for the RTT phenotypes, another attractive scenario is that the 
complete loss of 5hmC binding (Fig 2.12.D) is the primary cause of these latter 
clinical features of RTT. In this scenario, the R133C mutant of MeCP2 retains its 
5mC binding ability  to maintain repression of silent genes, whereas the fine 
tuning of accessible chromatin states via 5hmC-binding are disrupted. 
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•  Where is 5hmCpA?
Although this study identifies a new role for MeCP2 bound to 5hmCpA, there are 
still many unanswered questions: First, we still donʼt know the mechanism of how 
the CpA is hydroxymethylated in resting or activated states in the CNS. With the 
recent advancement in the sequencing techniques, it is now possible to 
sequence hydroxymethylomes genome-wide and in base-resolution (Flusberg, 
Webster et al. 2010; Huang, Pastor et al. 2010; Booth, Branco et al. 2012; Yu, 
Hon et al. 2012). Comparison of hydroxymethylomes and methylomes within cell 
populations or individual cells, and between active and resting states, will 
introduce the epigenetic information in the brain. It is now widely accepted that a 
quarter of global methylation occurs within non-CpG context (Ramsahoye, 
Biniszkiewicz et al. 2000; Lister, Pelizzola et al. 2009), yet an increased ratio of 
non-CpA dinucleotides within active gene bodies is highly  probable, since an 
enrichment of 5mCpA is observed in such regions. 
•  What are multiple identities of MeCP2?
We donʼt know the identity  of “populations” of MeCP2. Based on recent studies 
we postulate that one or more posttranslational modifications might be a switch 
for distribution of MeCP2 in such populations (Cohen, Gabel et al. 2011). It is 
also probable that the binding of MeCP2 to 5hmCpA is mechanistically different 
from its binding to 5mC (a hypothetical rearrangement of R133 residue of MeCP2 
is shown in Fig 2.15.B-C), causing a structural change in MeCP2 and its readout 
in downstream protein-protein interactions. On the other hand, due to the intrinsic 
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disorder of MeCP2, even if this kind of structural change was taking place, it may 
not have long range effects on the protein structure.
We do not have in vivo binding information of MeCP2. Since MeCP2 is a 
dynamically  bound protein that exists in different populations that occupy  different 
genomic regions at different times, a simple ChIP assay will bring down mixed 
populations of MeCP2 and, thus, will not be informative. For this kind of analysis, 
the identity  of different MeCP2 populations is a prerequisite. Complimentary to 
the identification of in vivo binding sites of MeCP2, comparison of changes in the 
distribution of 5hmC within euchromatin and heterochromatin in the absence of 
Mecp2 also would shed light into the contribution of MeCP2 species to the 
arrangement of chromatin states. This could be achieved by immunostaining 
5hmC and 5mC; and comparison of the layout of the chromatin around 
hydroxymethylated regions in different cell types between the KO and WT mice. 
In previous studies, smaller and more compact nuclei were observed in Mecp2 
deficiency (Chen, Akbarian et al. 2001; Cheung, Horvath et al. 2011). We have 
also observed a subtle decrease in the overall nuclease sensitivity of chromatin 
that is more pronounced in 5hmC-rich regions. 
We expect a great deal of insight into MeCP2 function to be revealed by in vivo 
studies with mice carrying R133C  mutation, where the balance between MeCP2 
populations is disrupted. If 5hmC-bound MeCP2 is involved in the fine regulation 
of the expression of certain neural genes, depending on the neuronal activity and 
cell type, then it is possible that 5hmC plays a role in the phenotypes that result 
in categorization of RTT as an Autism Spectrum Disorder. 
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•  What else is out there?
Currently  we do not have single-base resolution hydroxymethylome of the brain 
tissue. However we can expect that there still is a substantial amount of 5hmC 
within CpG context, which is not recognized by MeCP2. Therefore, alternative 
mechanisms may contribute to the decoding of 5hmC. We do not know whether 
5hmC-mediated demethylation events play  a role in the activity-dependent 
changes in the neuronal epigenome (Guo, Su et al. 2011) or if demethylation 
pathways are fundamentally different epigenetic mechanisms, carried out by a 
different subset of Tet enzymes during development. This finds support in the 
high level of DhMRs that are lost during neurodevelopment (Szulwach, Li et al. 
2011). We also do not understand where MBD3 binding to 5hmC in ES cells 
(Yildirim, Li et al. 2011) fits in this model. We cannot presently  answer these 
questions, yet in this study we have identified a novel MeCP2-mediated decoding 
mechanism of the epigenetic cryptogram that is unique to the brain and found an 
unexpected link to a critical new function for the RTT-causing protein MeCP2. 
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Chapter III.
Identification of a novel 5hmC-specific complex 
containing Purα 
III.I. A novel 5-hmC-specific complex in brain nuclear extract
! Although MeCP2 binding to 5hmC offers a new way of understanding the 
regulation of chromatin in the nervous system, it is possible that there are other 
novel 5hmC-binding proteins in the brain that were not detected in our studies 
previously due to methodological limitations. To further investigate this possibility, 
crude nuclear extract from rodent brain (Klose and Bird 2004) was directly 
assayed in EMSAs with radioactively labeled DNA probes containing C, 5mC or 
5hmC in the presence of an excess of non-specific DNA competitor at a range of 
dilutions. To our surprise, a 5hmC-dependent low-mobility complex was apparent 
at extract concentrations ~0.8 μg (Fig 3.1.A). This complex was much less 
obvious with probes containing C  or 5mC nucleotides. The quantification of the 
signal at the observed mobility  revealed 4- to 10-fold enhancement of 5hmC-
dependent signal at the observed location compared to the other probes (Fig 
3.1.B). The appearance of this complex was not tightly dependent on the amount 
of nonspecific competitor; however, when we competed the “hot” 5hmC probe in 
this complex with increasing concentrations of “cold” probe containing either C, 
5mC or 5hmC, the latter probe competed out the hot 5hmC probe slightly better 
than the others (Fig 3.1.C). This effect was especially clear when the competitor
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concentration was 150-fold of labeled probe. Although this specificity seemed 
subtle under our assay conditions, it was robust and reproducible. Hence we 
attempted to biochemically  purify and identify  the proteins that cause this specific 
activity, with the expectation of finding another decoding mechanism for 5hmC in 
the brain.
III.II. Biochemical purification of 5-hmC-specific complex
! First we prepared nuclear extract from 80 rat cerebella and fractionated it 
over a column coated with heparin, which has been used as a biomimetic 
polymer of DNA because it is a highly sulfated glycosaminoglycan and a linear 
negatively charged polymer with a size ranging from 5-30 kDa (Kiss, Kakkar et 
al. 1976; Farooqui 1980). Therefore heparin chromatography is a suitable way to 
separate DNA-binding proteins from the rest on nuclear proteins. Thus, highly 
concentrated nuclear extracts were applied on a heparin column at physiological 
conditions and extensively washed. The bound proteins were eluted by  gradually 
increasing the salt concentration from 0.15 to 1 molar (1M), collected in 
sequential fractions and assayed for their DNA binding. 
In our initial gradient elution (Δ[KCl] = 43 mM/min), we observed a 5hmC-specific 
complex that eluted at salt concentrations 0.4-0.55M. The complex resulted 
EMSA shift of similar distance from the free probe as the shift observed in NE 
(Fig 3.2.A). The signal intensity  of this 5hmC-specific complex in fraction 28 was 
two-fold of 5mC-containing complex (Fig 3.2.B). When we used a less steep 
gradient (Δ[KCl] = 20 mM/min), we observed a second, higher mobility complex 
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that eluted at lower salt concentrations, at 0.27-0.39 M (Fig 3.2.C), that was not 
present when the probe was made with 5mC. Since the mobility of both 
complexes were very close, it could be possible that the initial 5hmC activity we 
observed was made up of more than one species. Since we could biochemically 
separate these two species, we decided to purify them in parallel. A schematic 
flow of our biochemical purification is shown in Fig 3.3.A. Basically, we pooled 
fractions containing the later eluting complex (fractions 28 to 34 in 3.2.C, referred 
as complex A) and fractions containing the earlier eluting complex (fractions 
24-27, referred as complex B) separately. We applied both mixtures sequentially 
on a size exclusion column. The fractions that still showed the specific activity 
were once more pooled for each complex and applied on affinity columns that 
were coated with DNA containing 5hmC; and finally the bound proteins were 
eluted with a steep salt gradient. The fractions with the specific activity were 
pooled, concentrated and separated in SDS PAGE. Finally the bands that were 
visible after Coomassie stain were excised and identified by MS. The pooled 
fractions at each purification step  were analyzed by SDS PAGE followed by 
Coomassie staining (Fig 3.3.B) as a confirmation after each purification step. 
Finally, by mass pectrometry based database search, the proteins that co-purified 
with complex A were identified as Purine-rich element binding proteins, Purα and 
Purβ, in addition to Parp1 and Snrnp200 (Fig 3.3.C); while complex B co-eluted 
with a family  of heterogenous nuclear ribonucleoprotein AB (hnrnpAB), hnrnpD, 
hnrnpR and hnrnpU (Fig 3.3.D). 
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III.III. 5-hmC-specific complex contains Purα
! Previously, in our experiments, unlike MeCP2 NT (23 kDa), full-length 
MeCP2 (70 kDa) failed to enter the native gel from the wells. It is likely that full-
length MeCP2 is too large to penetrate through the pores of the acrylamide 
matrix, though its intrinsic disorder may be a factor as well. Based on this 
criterion, we focused on Purα, Purβ, hnrnpAB and hnrnpD, all of which are less 
than 50kDa. To check the presence of these proteins in the 5hmC-specific 
complex that we originally  observed, we first incubated the extract with 
antibodies against these proteins, then the competitor and the radioactive probe. 
The complex was clearly depleted by anti-Purα antibody without affecting other 
complexes within the lane, whereas the other antibodies did not show reactivity 
(Fig 3.4.A). Although this result gave us confidence that Purα was the strongest 
candidate to be the 5hmC-specific protein, it was not enough to exclude the 
possibility that other proteins might be involved, too. This could be due simply to 
low affinity of antibodies. Indeed, in our in vitro experiments, anti-Purβ antibody 
failed to deplete the recombinant Purβ/5hmC complexes (data not shown); we 
interpret the supershift assays using this antibody as inconclusive. When we 
reacted the anti-Purα antibody  with the purified complex A, we observed the 
supershift, as expected (Fig 3.4.B); however, the specificity of the complex was 
compromised during purification. 
As an additional control, we applied nuclear extracts directly  onto DNA affinity 
column containing 5hmC  and eluted at Δ[KCl] = 20 mM/min. After visual 
inspection fractions in SDS PAGE, we pooled fractions that contain similar 
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protein composition (Fig 3.5.A) and analyzed the binding of these pooled 
fractions to DNA as previously by Southern blot using radioactive probes 
containing C, 5mC and 5hmC (Fig 3.5.B) and EMSA (Fig 3.5.C). The Southern 
blots did not reveal any 5hmC-specific bands; however, we observed a protein in 
fraction pools 41-44 and 45-49 with specific binding to 5mC and 5hmC containing 
DNA at the size of MeCP2. Indeed, by MS we identified the protein band (marked 
with red dot adjacent to number 1) to be MeCP2, confirming our previous results. 
Additionally, the band of the correct size but in early fractions did not contain any 
MeCP2. The bands adjacent to numbers 2 and 3 were identified as Purα and 
Purβ, respectively. Intriguingly, the bands of this size at pool 37-40 contained 
several Hnrnps and low amounts of Purα or Purβ. Fraction 41-44 contained 
similar amounts of Hnrnps and Purα or Purβ, whereas fraction 45-49 contained 
exclusively Purα or Purβ. The increase in the amounts of Pur proteins in the later 
fractions as the elution conditions get more stringent also tracks with the specific 
activity  observed in the EMSA, confirming that Pur proteins are most likely the 
major components of the 5hmC-specific complex. The proteins marked with 4 
and 5 are identified as several subclasses of Histone H1. 
80
81
III.IV. Binding of recombinant hnrnps to 5hmC
! Although hnrnps are first described as a family of proteins, which bound 
nascent RNA transcripts (Choi and Dreyfuss 1984), their functions vary greatly 
(Han, Tang et al. 2010). HnrnpAB and D have also been implicated in DNA-linked 
processes as well, such as telomere maintenance (Ford, Wright et al. 2002; Chai, 
Zheng et al. 2003), transcription (Chai, Zheng et al. 2003) and replication 
(Campillos, Lamas et al. 2003). We expected the hnrnps to be a false positive; 
given that they are predominantly involved in RNA processes, combined with our 
findings that (1) their amounts of hnrnps negatively correlated with the specific 
activity  in fractions eluted from the DNA column, (2) the specific complex reacts 
with anti-Purα antibody  and not with anit-hnrnp  antibodies, and (3) in the 
competition assays the complex A (containing Pur proteins) behaves like the 
5hmC-specific complex in the crude extract. To confirm that hnrnps were indeed 
nonspecific, hnrnpAB and hnrnpD were produced in E.coli and purified using a 
His tag (Fig 3.6.A, left panel). To our surprise, when we assayed the DNA binding 
characteristics of these proteins at very low concentrations, both proteins formed 
a weak 5hmC-specific low mobility  complex in presence of competitor DNA (Fig 
3.6.B). The 5hmC-dependent signal of hnrnpAB was 4-fold of both C- and 5mC-
dependent signals (Fig 3.6.C, left), whereas in the case of hnrnpD this effect was 
around 2-fold (Fig 3.6.C, right). Interestingly, as the concentration of the hnrnpAB 
increased, the low mobility complex disappeared (Fig 3.6.C, black arrow) and a 
higher mobility complex started to appear (Fig 3.6.C, red arrow), the intensity  of 
which was independent of the DNA modification. We postulated that the basis of 
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these two different complexes with different binding characteristics might be 
explained by  the structural properties of these proteins: hnrnpAB and D contain 
two RNA recognition (RRM) domains (Hoffman, Query et al. 1991). RRM1 is 
highly conserved between hnrnpAB and hnrnpD, and so is RRM2; whereas the 
homology between RRM1 and RRM2 is much lower. It is then possible that 
RRM1 and 2 might have different characteristics for nucleic acid binding.  
It is possible that the low mobility  complex is formed when the probe is in excess 
and thus both RRMs are occupied by one radioactive probe; whereas when only 
on RRM is bound by a probe, then a higher mobility complex can be observed. If 
the remaining RRM is bound by the nonspecific competitor, the mobility of the 
complex will vary, causing a background smear. To directly  address this issue, we 
produced recombinant RRM1 and RRM2 of both hnrnps (Fig 3.6.A, right panel) 
and assayed their DNA binding. Their DNA binding efficiency was significantly 
reduced, but preliminary results indicated that RRM1 of hnrpAB is marginally 
more specific to 5hmC-containing DNA (Fig 3.6.E).
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III.V. Binding of recombinant Purs to 5hmC
! Purα together with Purβ and two isoforms of Purγ constitute a distinct and 
highly conserved class of PUR family that has been implicated in multiple roles in 
cellular and viral regulation of nucleic acids, including some neuronal genes in 
higher eukaryotes (Gallia, Johnson et al. 2000; White, Johnson et al. 2009). Purα 
expression increases during development with highest levels observed in bodies 
and dendrites in PCs, where the highest 5hmC levels also are observed 
(Kriaucionis and Heintz 2009). Purα-deficient mice die after birth with severe 
neurological pathologies (Khalili, Del Valle et al. 2003). They also are linked to 
leukemia (Lezon-Geyda, Najfeld et al. 2001), just as Tet genes (Kosmider, 
Delabesse et al. 2011; Lorsbach, Moore et al. 2003). Therefore Purα might be an 
important player in neural epigenetic regulatory mechanisms. 
Although not much is known about in vivo functions of Purβ, in situ hybridization 
data show that it is highly  enriched in PCs as well (http://mouse.brain-map.org/). 
To have insight into their binding characteristics, we produced recombinant 
proteins in bacteria (Fig 3.7.A). We observed some DNA binding activity  by each 
of these proteins with marginal preference for 5hmC (Fig 3.7.B). Recombinant 
Purα, when bound to unmodified or methylated probe formed two complexes with 
different mobilities. When unmodified, these complexed were of equal intensity. 
Upon methylation, the lower mobility complex seemed to be conserved whereas 
the level of the higher mobility  complex decreased, and this complex also 
migrated a little faster than the corresponding complex with C-containing probe. 
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In contrast, Purα formed a single lower mobility complex upon binding to 
hydroxymethylated DNA, which seemed to have higher levels compared to the 
other lanes, although this might simply be due to co-migration of two distinct 
complexes. Purβ forms a smear of low-mobility complexes with unmodified DNA, 
and the binding is much weaker when DNA is methylated. The intensity  of Purβ/
5hmC smear was slightly higher compared to Purβ/C  smear by visual inspection. 
We then quantified the signal intensities of the lowest mobility complex of each 
sample and derived a binding curve (Fig 3.7.C). The preference for 5hmC of both 
proteins was < 2-fold compared to other probes. Even at highest concentrations, 
these proteins failed to produce an SPR response on the DNA-coated surfaces 
(data not shown).
We suspected that the loss in specificity might be due to a co-factor that is not 
present in the in vitro binding reaction. Therefore we included increasing 
amounts of crude extract; however, it did not make a difference in the binding 
characteristics of these proteins (data not shown). Since Purα and Purβ can 
strongly interact with each other in a DNA-dependent as well as DNA-
independent way (Kelm, Cogan et al. 1999), we have also combined both 
proteins in the expectation that they might show cooperativity; unfortunately, 
incubation of these proteins prior to introduction of nucleic acid did not make a 
difference (data not shown). Endogenous Purs might be post-translationally 
modified in the 5hmC-specific complex, whereas the bacterially expressed 
recombinant proteins are not. Another alternative is that the crude extract 
contains a variety  of proteins that bind unmodified DNA and others that recognize 
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5mC-containing DNA and do not give access to Pur proteins; however, 5hmC is 
not preferred by many proteins so they occupy 5hmC sites. Under artificial 
conditions they are not selective for DNA modification. It is possible that these 
complexes also form with DNA containing C or 5mC in the nuclear extracts; 
however, they are bound by additional factors and migrate at much lower rates 
and therefore are not visible at the location we detect the 5hmC-dependent 
complex.
III.VI. Support for strand separation by Purs
Pur proteins consist of a glycine-rich flexible N terminus, a central nucleic acid 
binding core, with highest sequence conservation, and a C-terminal region, that 
is thought to be involved in protein interactions. The two nearly-identical PUR 
repeats interact with each other to form a PUR domain, which form two 
independent DNA binding surfaces, whereas a third PUR repeat facilitates the 
dimerization of Purα (Graebsch, Roche et al. 2009). The Pur proteins have been 
characterized by their binding to single-stranded DNA (ssDNA), double-stranded 
DNA (dsDNA), and ssRNA with a preference for GGN-repeats (Knapp, Ramsey 
et al. 2006). Purα is able to unwind duplex DNA, displacing the pyrimidine-rich 
strand while maintaining contact with the purine-rich strand (Wortman, Johnson 
et al. 2005). Since 5hmC might destabilize the duplex structure (Thalhammer, 
Hansen et al. 2011) we next asked whether the preference for 5hmC  could be 
simply because this modification expedites the strand separation for the PUR 
proteins. To test this idea we competed the “hot” 128 bp probe with short, 
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unlabeled and unmodifed ssDNA sequences (1-49, 38-86, 80-128 of radioactive 
probe). Indeed, only couple strands, but not their complimentary strand, could 
abolish binding to 5hmC even at very low concentrations (Fig 3.7.D). Their effect 
was weaker when the complimentary strand was added to the reaction, indicating 
that sequence-specific ssDNA binding is an essential mechanism for the DNA 
recognition of Pur proteins, although one strand did not contain a GGN repeat. 
Together this study proposes several candidates that might recognize 5hmC in 
vivo; however, their biological relevance still remains unclear. 
III.VI. Discussion
! The study presented here identifies a 5hmC-specific complex in the 
nuclear extracts from cerebellum and introduces new candidates for the 
decoding of 5hmC code in the brain. Although there is a lot to be done to 
characterize the biological function of these proteins upon binding to 5hmC, we 
present some convincing evidence that Purα is an integral component of this 
complex. The significant role and abundance of both 5hmC and Purα in PCs 
(Kriaucionis and Heintz 2009), combined with our results showing that in crude 
nuclear extracts there is a Purα-complex that associates with hydroxymethylated 
DNA up to 10-fold more avidly than unmodified or methylated DNA, suggest that 
this interaction might be crucial for neuronal function. In the brain Purα is found 
at high levels in Purkinje cells (Khalili, Del Valle et al. 2003; Hokkanen, Feldmann 
et al. 2011) with a peak of expression during critical periods of brain 
development, and in Purα -/- mice showing neurodevelopmental defects (Khalili, 
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Del Valle et al. 2003). Also high levels of 5hmC are present in both developing 
and adult brains (Ruzov, Tsenkina et al. 2011; Szulwach, Li et al. 2011). Together 
these data suggest a complex yet significant role for Purα protein in the brain. 
• Mysterious Purα
Although we were able to discover a Purα-complex with preference for 5hmC-
containing DNA, we still donʼt know if hydroxymethylated sites are occupied by 
this complex in vivo and more importantly what the downstream events are. We 
also donʼt know the other components of this complex, if there are any. To 
answer the first question, a cell-specific genome-wide ChIP-Seq experiment for 
Purα can be performed. Yet we still donʼt know how this interaction is functionally 
interpreted by Purα, since the functional data of Purα is controversial. It has been 
shown to function as a transcriptional activator (Haas, Gordon et al. 1993; Haas, 
Thatikunta et al. 1995; Zambrano, De Renzis et al. 1997) and repressor 
(Penberthy, Zhao et al. 2004; Subramanian, Polikandriotis et al. 2004), in 
addition to its various roles in both RNA- and DNA-dependent processes (Li, 
Koike et al. 2001; White, Johnson et al. 2009), including DNA repair (Kaminski, 
Cheeseboro et al. 2010). This data makes the interpretation of 5hmC-dependent 
role of Purα difficult to judge. It is likely that Purβ  is a component to the Purα-
complex, since Purα and Purβ  can strongly  interact with each other (Kelm, 
Cogan et al. 1999). Hnrnps may also be included, since their interaction with Pur 
proteins has been previously suggested (Li, Koike et al. 2001).
Moreover the binding of recombinant or purified Purα, as well as Purβ and 
hnrnps, to 5hmC was compromised. This may be due to limitations of in vitro 
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reconstitution assays. First, the recombinant proteins expressed in bacteria lack 
posttranslational modifications. This problem can be solved by switching to a 
mammalian expression system. Secondly, both recombinant and purified proteins 
were stripped from any co-factors or other binding partners. To overcome this we 
have supplemented the reaction with nuclear extract but did not observe any 
recovery. On the other hand, if there is a dose dependence then this strategy can 
be improved by first depleting the endogenous Pur proteins using an antibody, 
and then adding this to the recombinant Purα. In the assay conditions these 
proteins are very labile. In addition, with each purification step, the addition of 
albumin was increasingly necessary, indicative of high background non-specific 
binding.
• Specific, not specific
Although this complex appears specific in the crude extract, we could not detect 
a strong preference for recombinant Purα to 5hmC in vitro. Although it is highly 
probable that the in vitro conditions failed to reproduce the endogenous 
environment, we also have to consider the possibility that Purα-complex does not 
bind 5hmC  preferentially. We propose several explanations for this assumption: 
First, the fact that mammalian proteome contains thousands of DNA binding 
proteins (Kadonaga 2004), whereas only a few proteins are known to specifically 
recognize methylated sequences (Ballestar and Wolffe 2001; Fournier, Sasai et 
al. 2012). Although some DNA-binding proteins still may recognize their cognate 
DNA sequences when they are modified, it is reasonable to assume that a 
substantial fraction of these are displaced upon DNA modifications within their 
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binding sites. Therefore, even if in vitro binding of a protein to its target shows 
only subtle changes at different modification states, these may be translated to in 
vivo occupation of the majority  of hydroxymethylated sites by  such factors, since 
there is much bigger competition for an unmodified site. Since the nuclear extract 
represents a system that is close to the in vivo environment, it is very likely that 
this interaction has biological relevance. 
A second probable explanation is that the complex forms with each modification 
of DNA. However when it contains unmodified or methylated DNA, it is bound by 
additional factors and therefore it does not have the same mobility. If 5hmC 
causes formation of a complex that has different protein composition, this is still 
significant since it can potentially  explain the downstream events following the 
formation of this complex, the composition of which differs depending on the 
DNA modification. Finally it is also possible that one probe (128 bp) can 
accommodate more than one complex independently.
• The strand-separation hypothesis
A noteworthy  but simple model for the preferential interaction between 5hmC and 
Pur proteins is that the hydroxymethylated DNA is energetically “cheaper” for 
strand-separation by Pur proteins and therefore the binding kinetics are 
enhanced. If Purα is able to unwind duplex DNA to maintain contact with the 
purine-rich strand (Wortman, Johnson et al. 2005), then the pyrimidine-rich 
strand might be stabilized by another protein in the nuclear extract. When this 
protein is not present after purification of the reconstituted system, the unbound 
strand might be energetically too “costly” to maintain the preferential binding. 
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Indeed, an example for such interaction has been previously demonstrated, 
where Pur proteins strongly interacted with a pyrimidine-rich DNA-binding 
protein, MSY1 (Kelm, Cogan et al. 1999). Although this interaction was 
reproduced in the absence of DNA as well, it does not exclude the possibility that 
this kind of communication between proteins might be a significant biological 
process. However this implies that as an ssDNA competitor abolishes binding as 
in Fig 3.6.D, the complimentary strand then should then have the opposite effect, 
since it would stabilize the displaced strand of the original probe. This has not 
been observed in our experiments. Strand separation model also could explain 
the different mobilities of Pur/C, Pur/5mC  and Pur/5hmC  complexes. These could 
be simply two populations where the Pur protein is bound to one strand or the 
complimentary. Indeed, the molecular weight between strands is 0.27 kDa. Since 
the mobility  in the native gel might depend on factors other than molecular size, 
this small difference might explain this phenomenon. 
• What else is out there and how do we search?
In this study we identified a Purα-complex that binds 5hmC specifically. Yet our 
biochemical understanding of this complex is still limited and we do not have 
information on the functional meaning of this interaction. In addition, we still donʼt 
know which proteins occupy the rest of the hydroxymethylated sites, or whether 
they are depleted of proteins. We can improve and extend our strategies to find 
new candidates: First there is a large population of proteins that remain tightly 
bound to the chromatin after salt extraction and thus not subject to our analysis, 
whereas high salt concentration may be disruptive for certain proteins. Secondly, 
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the ionic conditions in gel shift assays might cause interactions to be lost. By 
enzymatic degradation of nucleic acids to get nuclear proteins, combined with 
further extending the detection methods more candidates may be screened. 
Finally, using different sequences as DNA baits that are modified in various 
contexts can increase the screening efficiency. 
Identifying the readers of the 5hmC code will contribute greatly  to the 
understanding of neuronal epigenetics, although it is also possible that 5hmC 
simply modifies the physical properties of the duplex DNA, changing the structure 
of chromatin, re-arranging nucleosomes, displacing methylation-specific factors 
or increasing accessibility  to proteins that bind ssDNA, which includes RNA 
Polymerase II. To decipher the 5hmC code and understand its true meaning, our 
studies need to encompass many possible scenarios, some of which may be 
occurring in concert. However in the words of Albert Einstein “[A]s our circle of 
knowledge expands, so does the circumference of darkness surrounding it.”
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Materials and Methods
Preparation of Probes
! C, 5mC and 5hmC probes were prepared using either unmodified dCTP 
(New  England Biolabs), 5ʼ-methylated dCTP (Trilink Biotechnologies, San Diego, 
CA, USA) or 5ʼ-hydroxymethylated dCTP (Bioline, Taunton, MA, USA), along with 
dATP, dTTP and dGTP (New England Biolabs). A 120 bp region of mouse BDNF 
promoter was amplified with ChoiceTaq (Denville, South Plainfield, NJ, USA) 
according to manufacturerʼs recommendations using 5ʼ-biotinylated or 5ʼ-
unmodified forward primers and 5ʼ-unmodified reverse primers (Genelink, 
Hawthorne, NY, USA) listed below. For CG-rich probe we amplified a 200 bp 
region of the pUC  plasmid (Invitrogen). Probes were purified via Qiaquick PCR 
Purification Columns (Qiagen). 1 pmol of probe was end-labeled with 1 or 10 uCi 
of γ-P32 dATP (Perkin Elmer, Waltham, MA, USA) using T4 Polynucleotide 
Kinase (New England Biolabs) for 45 min at 37°C  and purified using Illustra 
ProbeQuant G-50 Micro Columns (GE Healthcare, Little Chalfont, UK). 32P was 
counted in scintillation fluid Ready Safe (Beckman Coulter) in 1209 Rackbeta 
scintillation counter (LKB-Wallac Pharmacia, Turku, Finland).  
primer sequence
BDNF F GCGTGAATTTGCTAGGACTGG
BDNF R GAATTACCAGAATCAGAATTCCG
CG-rich F GTGAGCTAACTCACATTAATTG
CG-rich R TGCTCACATGTTCTTTCCTG
probe 1 (p1) F GCCCATTCTTTCTTGATAGATTTTAGTTGTTCAAC
probe 1 (p1) R TGAGCATCCTGGCGAGCATAG
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probe 2 (p2) F GCCCACAATAAACCAGCCACTTACCAG
probe 2 (p2) R GGGAGATGTTCTGGCCTCTCAG
probe 3 (p3) F GTAAGCTGATGGAAAACTGCTGTTG
probe 3 (p3) R AGCCAACTCTCTAAGAGATGGACCTCAC
single-site F CATGAATAAAACATCTACAAAATCAACCCTAAAAC
single-site R TCGACCATTTAAAATATACATCTTTCCTATTAAAC
CGCt AATAAAACATCTACAAAATCAACCCTAAAACcgcTTTAATAGGAAAGATGTATATTTTAAATGG
CACt AATAAAACATCTACAAAATCAACCCTAAAACcacTTTAATAGGAAAGATGTATATTTTAAATGG
CCCt AATAAAACATCTACAAAATCAACCCTAAAACcccTTTAATAGGAAAGATGTATATTTTAAATGG
CTCt AATAAAACATCTACAAAATCAACCCTAAAACctcTTTAATAGGAAAGATGTATATTTTAAATGG
CGA AATAAAACATCTACAAAATCAACCCTAAAACcgaTTTAATAGGAAAGATGTATATTTTAAATGG
CAA AATAAAACATCTACAAAATCAACCCTAAAACcaaTTTAATAGGAAAGATGTATATTTTAAATGG
CGT AATAAAACATCTACAAAATCAACCCTAAAACcgTTTAATAGGAAAGATGTATATTTTAAATGG
CAT AATAAAACATCTACAAAATCAACCCTAAAACcaTTTAATAGGAAAGATGTATATTTTAAATGG
1+ GCGTGAATTTGCTAGGACTGGAAGTGAAAACATCTACAAAGCATGCAAT
1- ATTGCATGCTTTGTAGATGTTTTCACTTCCAGTCCTAGCAAATTC ACGC
2+ CAAAGCATGCAATGCCCTGGAACGGAATTCTTCTAATAAAAGATGTATC
2- GATACATCTTTTATTAGAAGAATTCCGTTCCAGGGCATTGCATGCTTTG
3+ ATAAAAGATGTATCATTTTAAATGCGCGGAATTCTGATTCTGGTAATTC
3- GAATTACCAGAATCAGAATTCCGCGCATTTAAAATGATACATCTTTTAT
Nuclear protein extracts from cerebella
! Nuclear extracts were prepared from 80 frozen rat cerebella (Pel-Freez, 
Rogers, AR, USA) as previously described (Klose and Bird 2004). Briefly, rat 
brains were diluted 5 volumes to 1 in ice-cold Buffer A containing 10 mM Hepes 
pH 7.5, 25 mM KCl, 0.15 mM spermine, 0.5 mM spermidine, 1 mM EDTA, 2 M 
sucrose, 10% glycerol, and Halt Protease and Phosphatase Inhibitor Cocktail 
(Pierce Biotechnology, Rockford, IL, USA) followed by homogenization in a 60 
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mL Dounce (Bronwill Scientific Inc., Rochester, NY) on Glas-Col Tissue 
Homogenizer (Cole-Parmer, Vernon Hills, IL, USA) (5 strokes at 4,000 rpm). The 
homogenate was layered onto a 10 mL cushion of the Buffer A and centrifuged in 
pre-chilled SW2 (Beckman Coulter) rotor at 24,000 revolutions per minute (rpm) 
in Beckman XL-70 ultracentrifuge for 1 hour at 2 °C. Recovered nuclei were 
incubated in 5 volumes of Buffer B containing 20 mM Hepes (pH 7.9), 150 mM 
KCl, 1 mM EDTA, 0.5 mM DTT, Halt Protease and Phosphatase Inhibitor Cocktail 
on ice 2 min and then resuspended. The nuclei were counted by Neubauer 
haemocytometer (Hausser Scientific, Horsham, PA, USA). The nuclear proteins 
were extracted by stepwise addition of 3M KCl until a final concentration of 400 
mM. The extraction was allowed to proceed for 20 min on ice, and then the nuclei 
were pelleted at 13,000 rpm for 10 min at 4°C. The supernatant was dialyzed in 
Slide-A-Lyzer cassettes with 10 kDa molecular weight cutoff (Pierce) overnight at 
4°C against Buffer B. The protein concentration was measured by  Quick Start 
Bradford Assay (BioRad) according to manufacturerʼs instructions. For fast 
protein liquid chromatography, 10 mL of the dilate was collected and centrifuged 
5 min at 14,000 rpm. The cleared lysate then was concentrated in Amicon15 10K 
MWCO (Millipore) 20 min at 4,000 rpm at 4°C  or until the extract is down to 4 mL. 
Alternatively, nuclear extracts were prepared from 10 wild type (WT) or ECP2 KO 
mice using SW41 rotor with a 2 mL cushion of Buffer A. 
5hmC affinity pull-down
" 10 ug of 5ʼ-biotinylated C, 5mC or 5hmC BDNF probe was immobilized on 
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Dynabeads M-280 Streptavidin (Invitrogen) following manufacturerʼs 
recommendations and incubated with 2 mg of nuclear extract in presence of 1 
mg of poly-dIdC  competitor (Sigma Aldrich) in Buffer B supplemented with 1% 
Triton X-100 (Sigma Aldrich) 1 hour at room temperature. The isolated proteins 
were washed extensively and eluted in 1X LDS Sample Buffer (Invitrogen) under 
reducing conditions, separated by gel electrophoresis in 4-12% gradient BisTris 
Gels (Invitrogen) and stained by GelCode Blue (Pierce) or Silver Stain Kit 
(Pierce). Protein bands were excised from a GelCode stained gel and analyzed 
by mass spectrometry (MS). Alternatively, nuclear extracts prepared from WT or 
KO mice were incubated with magnetic beads coated with 5ʼ-Biotinylated CG-rich 
probes. Nuclei from Mecp2tm1.1Bird hemizygous males were a gift from Dr Adrian 
Bird.
MeCP2 immunoprecipitation
" 40 ug of 5ʼ-biotinylated probe containing CpG, 5mCpG, 5hmCpG, CpA, 
5mCpA and 5hmCpA was immobilized on Dynabeads M-280 Streptavidin 
(Invitrogen) following manufacturerʼs recommendations. 10 mg of nuclear extract 
supplemented with 0.5 mg of poly-dIdC competitor (Sigma Aldrich) in Buffer B 
was incubated with the DNA-coated beads for 1 hour at room temperature. The 
isolated proteins were washed extensively and eluted for 30 min in Buffer N 
containing 400 mM NaCl, 50 mM Hepes pH 7.9, 1 mM EDTA, 10 mM DTT, 0.5% 
SDS and 10 units/ml of Benzonase (Sigma). 50 ug of anti-MeCP2 antibody (Cell 
Signaling) was coupled to Dynabeads Protein A (Invitrogen) in Buffer B 
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supplemented with 0.5% Igepal (Sigma) according to manufacturerʼs 
recommendations. The eluates in Buffer N were diluted 1:5 in Buffer B  and 
incubated with MeCP2-coated beads for 2 hours at room temperature. The 
proteins bound to beads were eluted in 1X LDS Sample Buffer (Invitrogen) under 
reducing conditions, separated by gel electrophoresis in 4-12% gradient BisTris 
Gels (Invitrogen) and assayed by Western blotting.
Western blotting
! For Western blotting, the extracts denatured in sample buffer (Invitrogen) 
under reducing conditions, and eluates prepared as described above, were 
separated on a pre-cast Bis-Tris SDS-gel (Invitrogen) via electrophoresis and 
transferred on a PVDF-membrane (Biorad). The membrane was blotted with 
primary antibodies, anti-MeCP2 (Upstate) antibody in combination with horse-
radish-peroxidase-conjugated secondary  antibody (Pierce) or anti-
phosphoserine-HRP (Abcam). The chemiluminescence was detected by the 
application of the ECL substrate (Pierce). 
Southwestern Blotting
! Nuclear extract (isolated as described above) was separated on duplicate 
gels and transferred to PVDF membranes (BioRad) in Mini Trans-Blot 
Electrophoretic Transfer Cell (BioRad) at 100 V for 2 hours at room temperature 
and assayed for DNA binding as previously described (Campoy, Meehan et al. 
1995). The blotted proteins were re-natured by immersing the blot in Buffer B 
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with 6 M guanidine HCl, which was then serially diluted to 3, 1.5, 0.75, 0.375, 
0.188, and 0.094 M using binding Buffer B with incubation at 4°C  for 5 min each 
time. The blot was blocked at room temperature for 30 min in Buffer B containing 
5% non-fat milk, then incubated with 105 cpm/mL CG-rich 5mC  or 5hmC probes 
with 10 ug/mL poly-dIdC  for 2 hours at room temperature, extensively  washed 
with Buffer B and air-dried. The autoradiography was measured by exposing a 
storage phosphor screen (Molecular Dynamics, Sunnyvale, CA) that was 
scanned by Typhoon Imager (GE Healthcare) and analyzed by ImageJ software. 
Expression and purification of recombinant proteins  
! cDNA clones of human MeCP2, and MBD family  of proteins were 
purchased from Open Biosystems (Lafayette, CO) and cloned into pet28a vector 
(Novagen, Madison, WI, USA) using primers listed below with NdeI and XhoI 
(NEB) restriction sites.
primer sequence
MeCP2 NT 
(aa 1-205) F ATGGTAGCTGGGATGTTAGGGCTCAGGGAAG
MeCP2 NT 
(aa 1-205) R AGACCCAAGGCGGCCACGTCA
MeCP2 MBD 
(aa 77-167) F
GCTACCGGACTCAGATCTCGAGCTCAACGCCACCATGGCTTCTGCCT
CCCCCAAACAGCG
MeCP2 MBD 
(aa 77-167) R
CCGCGGTACCGTCGACTGCAGAATTCGACCGGGAGGGGCTCCCTCT
CCC
MeCP2 (aa 1-486) F ATGGTAGCTGGGATGTTAGGGCTCAGGGAAG
MeCP2 (aa 1-486) R GCTAACTCTCTCGGTCACGGGCGTCCGGCTGTCCAC
100
MBD1 (aa 1-144) F ATGGCTGAGGACTGGCTGGACTGCCCG
MBD1 (aa 1-144) R GCCATCCCCTGAGAAGCTGATTCCACAGTTCTCACAGCAC
MBD2 (aa 141-319) F ATGGCCACGGAGAGCGGGAAGAGGATGGATTGCCCGGCCCTCCCCCCCG
MBD2 (aa 141-319) R CTCATCATTGCTACCTGGACCAACTCCTTGAAGACCTTTGGGTAG
MBD3 (aa 1-259) F ATGGAGCGGAAGAGCCCGAGCGGGAAGAAGTTC
MBD3 (aa 1-259) R GTGCTCCATCTCCGGGTCCGGGTCG
MBD4 (aa 1-197) F ATGGGCACGACTGGGCTGGAGAGTCTGAGTCTG
MBD4 (aa 1-197) R CTCTGAACTACTACTTGGCGGCATAAACACATCCTTTTTGC
L100V Rin GTGTCCAGCCTTCAGGCACGGTGGG
L100V Fin GTGCCTGAAGGCTGGACACGGAAGC
D121G Rin CTTTTCCCTGGGGATTGATCAAATACACACCATACTTCCCAG
D121G Fin GTGTGTATTTGATCAATCCCCAGGGAAAAGCCTTTC
R133H Rin ACTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
R133H Fin CGAAGTACGCAATCAACTCCACTTTAGAGTGAAAGGCTTTTC
R133C Rin TGCTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAG
R133C Fin GTACGCAATCAACTCCACTTTAGAGCAAAAGGCTTTTC
S134C Rin GTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGC
S134C Fin CGAAGTACGCAATCAACTCCACTTTACAGCGAAAGGC
S134F Rin TTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
S134F Fin CTTTTCGAAGTACGCAATCAACTCCACTTTAAAGCGAAAGGCTTTTC
E137G Rin CTACCTTTTCGAAGTACGCAATCAACCCCACTTTAGAG
E137G Fin GGTTGATTGCGTACTTCGAAAAGGTAGGCGACAC
A140V Rin GTGTCGCCTACCTTTTCGAAGTACACAATCAACTCCAC
A140V Fin TGTACTTCGAAAAGGTAGGCGACACATCCCTGGAC
R133M Rin GAAGTACGCAATCAACTCCACTTTAGACATAAAGGCTTTTC
R133M Fin ATGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
R133K Rin GAAGTACGCAATCAACTCCACTTTAGACTTAAAGGCTTTTC
R133K Fin AAGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
R133E Rin GAAGTACGCAATCAACTCCACTTTAGACTCAAAGGCTTTTC
R133E Fin GAGTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
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R133S Rin GAAGTACGCAATCAACTCCACTTTAGAGCTAAAGGCTTTTC
R133S Fin AGCTCTAAAGTGGAGTTGATTGCGTACTTCGAAAAGGTAGGCGAC
purα F ATGGCGGACCGAGACAGCGGC
purα R ATCTTCTTCCCCTTCTTCCTCACCCTG
purβ F GCGGACGGCGACAGCGGC
purβ R ATCCTCATCCACCTCCTCACCCTC
hnrnp AB F ATGTCGGACGCGGCTGAGGAGC
hnrnp AB R GTATGGCTTGTAGTTATTCTGATGAC
hnrnp D F ATGTCGGAGGAGCAGTTCGGAG
hnrnp D R GTATGGTTTGTAGCTATTTTGATGTCCACCTCG
hnrnp AB R1 F ATGTCGGACGCGGCTGAGGAGC
hnrnp AB R1 R CATAGCCATAGCCTTTTTAGGGTC
hnrnp AB R2 F ATGGCTATGAAGAAGGACCCTG
hnrnp AB R2 R GTATGGCTTGTAGTTATTCTGATGAC
hnrnp D R1 F ATGTCGGAGGAGCAGTTCGGAG
hnrnp D R1 R TCTTTTGTTTTCATGGCTTTG
hnrnp D R2 F GAGCCTGTCAAAAAAATTTTTG
hnrnp D R2 R GTATGGTTTGTAGCTATTTTGATGTCCACCTCG
The C-terminally 6-His tagged recombinant proteins were expressed in BL21 
strain of E. coli (Invitrogen) in Overnight Express Autoinduction System (EMD 
Millipore, Billerica, MA, USA), purified using Ni-NTA Spin columns (Qiagen) 
according to manufacturerʼs recommendations and dialyzed against Buffer B 
supplemented with 10% glycerol. The protein concentration was measured by 
Quick Start Bradford Assay (BioRad). 
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Electrophoretic mobility shift assay (EMSA)
! Unless stated otherwise, 1 pmol of  MeCP2 (aa 1-205), 1.2 pmol of MBD1, 
0.5 pmol of MBD2, 50 pmol of MBD3 or 2.5 pmol of MBD4 was incubated with 10 
fmol of 32P-end-labeled C, 5mC or 5hmC BDNF probe in presence of 1 µg of 
pdIdC in Buffer B supplemented with 5% Ficoll for 30 min at room temperature 
(RT). 10 μL of the binding reaction was electrophoresed in native 6% 29:1 
acrylamide:bis-acrylamide gel in 0.5 % TBE buffer at 4°C for 2-4 h. The gels were 
then dried in vacuum (Fisher Scientific, Hampton, NH, USA) for 1 h at 70°C, 
exposed to a storage phosphor screen (Molecular Dynamics) and scanned by 
Typhoon Imager (GE Healthcare). For assays with crude nuclear extracts, 
concentrations ranging from 60 ng to 2 μg were first incubated with 5-10 μgs of 
polydIdC  for 10 min at RT and then with 2.5-10 fmoles of radioactive probe. For 
heparin fractions, a total of 4 μL of the pool, 2.5 μg polydIdC  and 2.5 fmoles of 
probe was used. For size-exclusion and affinity column fractions, a total of 20 μL 
of the pool was used with 0.5 μg polydIdC and 5 fmoles of probe.
Surface Plasmon Resonance
! Four flow cells (Fc) of Streptavidin (SA)-Sensor Chips (GE Healthcare) 
were cleaned with 3, 1-min pulses of 1M NaCl in 50mM NaOH in Biacore 3000 
(GE Healthcare). 5ʼ-biotinylated C, 5mC and 5hmC  BDNF probes were injected 
onto Fc 2, 3 and 4, respectively, at 2  μL/min in Buffer B until SPR response 
increased by 500(+/-25) Resonance Units (RU). Fc 1 was immobilized with 2 mM 
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Biotin to serve as reference cell. 8-12 serial dilutions of protein samples within 
0.01 Kd to 10 Kd range in Buffer B supplemented with 0.02% Tween and 50 ng/
μL poly-dIdC were injected onto each Fc in parallel at 30 μL/min for 3 min. The 
surfaces were regenerated by 1 min injection of Buffer B with 1.5 M KCl (Buffer 
C).  The change in SPR response with respect to reference cell 5 seconds before 
the end of injection was recorded for steady state  analysis.  Each run was 
performed in duplicates and each  experiment was repeated with at least 4 
samples of each protein preparation on two independently prepared  surfaces. 
Bmax values and their standard error were automatically extracted in GraphPad 
Prism Software from  steady state values and they were divided by the 
corresponding protein size. The F test to compare variances was performed 
using GraphPad Prism software.
The new generation SPR analysis was performed using ProteON XPR36 protein 
interaction array system (Bio-Rad). The NLC Sensor Chip  (Bio-Rad) was 
preconditioned according to manufacturerʼs instructions. biotinylated DNA 
probes, prepared as described above, at 10 ng/μl were applied vertically at 30 μl/
min for 5 min or until the resonance of each surface reached 550 (+/-40) RU. 
One channel was immobilized with 2 mM Biotin to serve as reference cell. 15 
serial dilutions of protein samples within 0.01 Kd to 10 Kd range in Buffer B 
supplemented with 50 ng/μL poly-dIdC  were injected onto each Fc in parallel at 
100  μL/min for 2 min. The surfaces were regenerated by 18 sec injection of 
Buffer B with 1.5 M KCl (Buffer C). 
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 Southeastern Blot
! 18 million nuclei from cerebella of WT or KO mice were resuspended in 
buffer containing 10 mM Tris pH 8.0 and 150 mM NaCl supplemented with 5mM 
CaCl2, 10 mM Na-butyrate, 0.15 mM spermine, 0.5 mM spermidine and Halt 
Protease and Phosphatase Inhibitor Cocktail (Pierce). The nuclei were partially 
digested by the addition of 100 Kunitz units of Micrococcal Nuclease   (NEB) and 
aliquots of the reaction were stopped by the addition of excess amount of EGTA 
at various time points. The nuclei were then incubated with RNase A/T1 Mix 
(Fermentas) lysed in 1% SDS and incubated with Proteinase K for at 37°C for 30 
min and 65°C  for 30 min. The DNA was extracted with phenol: chloroform: 
isoamyl alcohol (25:24:1), precipitated in 70% ethanol and dissolved in Tris-
EDTA buffer. 0.5-1 µg of DNA was resolved in 2% TAE agarose gel and 
transferred to nitrocellulose membrane (Whatman pIc, Maidstone, Kent, UK) 
overnight by capillary action in 20X SSC buffer (3M NaCl, 300mM Na-Citrate) 
following denaturation in 0.4 M NaOH and 0.6 M NaCl and neutralization in 0.5 M 
Tris (pH 7.5) and 1.5 M NaCl of the agarose gel. The membrane was equilibrated 
in 6X SSC buffer, air-dried, UV-crosslinked, blocked in 5% fat-free milk in TBS 
buffer with 0.2% Tween and incubated with rabbit anti 5hmC antibody (1:500, 
Active Motif) or mouse anti 5mC  antibody (1:250, Diagenode, Denville NJ, USA) 
for 2 hours at room temperature. The membranes were washed for 3 X 5 minutes 
and  incubated with a secondary antibody conjugated with horse radish 
peroxidase (1:4000, Abcam) for 30 min at room temperature. The blots were 
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washed for 3 X 10 minutes, rinsed with water and then reacted with ECL 
substrate (Pierce). The signal was detected by exposing reacted blots to 
chemiluminescence films (Sigma Aldrich) that were developed in film processor 
(Konica Minolta, Osaka, Japan). The gel images from five gels from three 
independent experiments were analyzed in ImageJ software. The average 
values, standard error of the mean and p values by unpaired t-test were 
calculated via GraphPad Prism Software. We refer to this method as 
Southeastern blot, since it combines the transfer of an electrophoretically 
separated DNA sample onto a membrane as in classical Southern blot technique 
with the assaying of chemical modifications as in Eastern blot technique  
Fast protein liquid chromatography
! All fast protein liquid chromatography (FPLC) experiments were performed 
in ÄKTAFPLC  system (GE Healthcare). A 5mL HiTrap Heparin HP column was 
attached to the system after washing the system with MilliQ water and Buffer C , 
and then the upstream of column with running buffer, Buffer B. The flow started at 
5 ml/min, 0% B for at least 10 min, such that the column was equilibrated with 
ten-fold volumes of running buffer. A 5 mL injection loop was attached and also 
equilibrated with 10 volumes of running buffer. The concentrated and precleared 
extract was injected manually into the loop, the flow was lowered to 2 mL/min the 
flow path was changed to “inject”. 2 mL fractions were collected throughout the 
run. After 6 volumes of running buffer passed through the column for 15 min, a 
gradient elution process started such that the concentration of Buffer C  increased 
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from 0% to 100 % in 45 min. The run was stopped when the system was 
saturated with 100% buffer C and the fractions were assayed by EMSA. 
For size-exclusion chromatography, Superdex 200 HR 10/30 (GE Healthcare) 
was used. The system was washed with MilliQ water prior to attaching column, 
and column was equilibrated at 0.5 mL/min with 2 volumes of MilliQ water (50 
mL) and 2 volumes of Buffer B, adjusted to KCl concentration equivalent to that 
of the fractions. A  250 μL injection loop was also attached and washed with 2 mL 
of this buffer. The heparin fractions containing the specific activity were then 
pooled, concentrated to a total volume of less than 250 μL, precleared and 
injected manually.  The run was let to proceed at 0.2 mL/min until  one volume 
buffer B was allowed to flow through. 0.5 mL fractions were collected. 
For DNA-affinity column, 1 mL HiTrap Streptavidin HP column was attached to 
the system after washing the system with MilliQ water and Buffer Bind & Wash 
(BW), containing 5 mM Tris‧HCl pH 7.5, 0.5 mM EDTA pH 8.0 and 1 M NaCl. The 
column was equilibrated with ten-fold volumes of buffer BW  at 1 mL/min. A 1 mL 
injection loop was attached and also equilibrated with 10 volumes of buffer BW. 
100 μg biotinylated DNA probe containing C, 5mC or 5hmC (described above) 
was injected manually. The binding was allowed to proceed at 0.05 mL/min for 20 
min and additional volumes of buffer BW  was run through the column. Next, the 
column was detached from FPLC system. The system was washed with MilliQ 
water and Buffer C, and then the upstream of column with Buffer B. The column 
was re-attached and was equilibrated with ten-fold volumes of running buffer at 
0.5 ml/min. The size exclusion fractions containing the specific activity were 
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pooled, concentrated to a total volume of less than 1mL, precleared and injected 
manually, after the injection loop was also equilibrated with 10 volumes of buffer 
B. The flow was lowered to 0.4 mL/min the flow path was changed to “inject”. 1 
mL fractions were collected throughout the run. 
Mass spectrometric identification of isolated proteins. 
! MS analysis was conducted by the Proteomics Resource Center at The 
Rockefeller University, New York, NY. Protein bands were reduced and alkylated 
and hereafter subjected to in-gel trypsinization following published protocol. 
(Shevchenko, Wilm et al. 1996). Post digestion, peptides were extracted and 
separated by reversed phase based nano flow liquid chromatography (Dionex, 
Boston, MA, USA) connected to an Orbitrap  XL mass spectrometer (Thermo, 
San Jose, CA, USA). Peptides were subjected to Tandem MS in CID mode. 
Tandem MS data were extracted using ProteomeDiscoverer v. 1.3 (Thermo, 
Bremen, Germany) and queried against the Rat International Protein Index (IPI 
rat) v 3.87 using MASCOT 2.3 (Matrixscience, London, UK). For each identified 
protein a rough measure of amount was calculated based on the average area of 
the three most abundant peptides (Silva, Gorenstein et al. 2006). 
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Animal protocols
All protocols involving animals were approved by the Rockefeller University 
Institute Animal Care and Use Committee (protocol number #08114) in 
accordance with the National Institute of Health (NIH) guidelines. C57BL/6J mice 
an. Mecp2tm1.1Bird hemizygous males were purchased from Jackson Labs at 4 
weeks of age. Animals were sacrificed between 7 to 11 weeks of age for 
experimentation, unless otherwise indicated. All mice were maintained on a 12 h 
light/dark cycle and given ad libitum access to food and water.
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Appendix A
A new method for transient, drug-dependent and cell-
specific inhibition of global translation in vivo
A.I. Aim
! This study tries to examine the requirement for protein synthesis in 
specific cell populations in the brain during memory consolidation. To achieve 
this, we engineered an endogenous translational inhibitor to become drug-
inducible. We then generated genetically  modified mice that carry this 
engineered construct under a conditional and ubiquitous promoter, such that the 
inhibitor will only be activated in cells that co-express the appropriate 
recombinase. In such mouse lines, that express the recombinase in specific cell 
populations, we can block protein synthesis temporarily  and in a cell-specific 
manner. This way, the requirement of protein synthesis in variety  of neuronal 
subpopulations for different stages and types of memory consolidation can be 
systematically tested. 
A.II. Background: long term memory and protein synthesis
! Memory is broadly defined as the capacity of an organism to encode, 
store and retrieve information. Since Ebbinghausʼ seminal research in 19th 
century (Ebbinghaus 1885), clinical (Scoville and Milner 1957; Squire, Cohen et 
al. 1984; Zola-Morgan, Squire et al. 1986), anatomical (Squire, Amaral et al. 
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1990; Smith and Jonides 1997), genetic (Jones, Errington et al. 2001; Schmitt, 
Deacon et al. 2003) and molecular studies continue to investigate the 
involvement of neuroanatomical regions in different stages and types of memory 
formation (Gooney, Shaw et al. 2002). The current cortical memory consolidation 
scheme starts with the reciprocal strengthening of hippocampal-cortical 
connections by the simultaneous activation of these areas (Marr 1970; 
Sutherland and McNaughton 2000; Wittenberg, Sullivan et al. 2002). Then, the 
intracortical connections strengthen until the memory  trace becomes 
hippocampus-independent and stable (McClelland, McNaughton et al. 1995; 
Graham and Hodges 1997; Dudai 2004).
The first clues that de novo protein synthesis might be necessary for long-term 
memory (LTM) formation came about in the 1960s, when chemical protein 
synthesis inhibitors blocked LTM leaving the short-term memory (STM) intact 
(Flexner, Flexner et al. 1963). Upon LTM-inducing training events, enhanced 
translation activity  (Martin, Casadio et al. 1997) and activated signaling events 
that trigger gene expression (Bartsch, Casadio et al. 1998; Malleret, Haditsch et 
al. 2001) were recorded. Although current techniques provide compelling 
evidence on mechanisms of memory formation; some are invasive (Alberini 
2008; Rudy 2008) and may result in convoluted phenotypes, while noninvasive 
imaging techniques do not provide sufficient molecular details. In addition, data in 
cell-type resolution is not yet available. By combining a genetic targeting with a 
switch by a nontoxic molecule, the strategy presented here offers an alternative, 
temporal, noninvasive and cell-specific way to solve questions raised in this field.
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A.III. Background: mammalian protein synthesis 
! Protein synthesis is tightly  regulated in mammalian cells at the level of 
initiation, that being the first and the rate-limiting step  (Kaufman 1994). The 40S 
ribosome associates with eukaryotic initiation factors (eIF) 1A and eIF3 and a 
ternary complex, made of eIF2, initiator methionyl-tRNA and GTP; and forms the 
43S pre-initiation complex. eIF4E, eIF4A and eIF4G together form the cap-
binding complex, which recruits the ribosome complex on mRNA. 40S ribosome 
starts scanning the mRNA until it encounters a start codon, where 60S ribosome 
joins in and elongation starts while eIFs are sequentially  released (Mathews, 
Sonenberg et al. 2007). eIF2 and eIF4E are primary targets for translational 
control by cellular mechanisms, in addition to cleavage of eIF4G and other eIFs 
by caspases or exogenous proteases (Fig A.1.A) (Holcik and Sonenberg 2005). 
Several 4E-binding proteins (4E-BPs) regulate the cap-dependent translation 
while phosphorylation of eIF2α by one of the four stress-induced protein kinases 
prevents the formation of the ternary complex and inhibits the general protein 
synthesis except some mRNAs that carry  regulatory sequences as escape 
mechanism (Fig A.1.B) (Richter and Sonenberg 2005; Wek, Jiang et al. 2006).
A.IV. Background: effect of protein synthesis inhibitors in brain
! GCN2 is the major eIF2α-kinase in the brain (Berlanga, Santoyo et al. 
1999; Sood, Porter et al. 2000). Gcn2 -/- mice show mpaired hippocampus-
dependent forms of LTM leaving amygdala-dependent LTM unaffected (Costa-
Mattioli, Gobert et al. 2005). Interestingly these mice have enhanced memory 
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with weak training protocols. Similar results were obtained with eIF2α+/S51A mice 
that show decrease basal eIF2α phosphorylation (Costa-Mattioli, Gobert et al. 
2007). Conversely, Sal003, an inhibitor of eIF2α-dephosphorylation, impairs LTM. 
Decreased hippocampal eIF4E phosphorylation was observed in another study 
shortly after training (Kelleher Iii, Govindarajan et al. 2004). Two of the eIF4E-
BPs are inactivated by induction of LTM (Banko, Hou et al. 2006; Gelinas, Banko 
et al. 2007). Hippocampal slices from 4E-BP2 -/- mice had lowered threshold for 
LTP. Interestingly in these mice the hippocampus-dependent LTM was impaired 
(Banko, Poulin et al. 2005) whereas the cortex-dependent memory was 
enhanced (Banko, Merhav et al. 2007).
Among the four eIF2α-kinases (Fig A.1.A), RNA-dependent protein kinase or 
protein kinase R (PKR) inhibits global translation in response to viral infection 
(Holcik and Sonenberg 2005; Wek, Jiang et al. 2006). There are two ways that 
activate PKR: Homodimerization of N-terminal regulatory region upon binding 
viral dsRNA and subsequent autophosphorylation of the kinase domain; or the 
cleavage of the regulatory domain from the constitutively  active kinase domain 
(aa 252-551; PKRkin) by virally induced caspases. Dimerization of PKR can be 
chemically induced by replacing the N-terminal domain of PKR with a well 
established FKBP domain, which can be dimerized via a synthetic ligand, 
AP20187. This method can effectively  block protein synthesis in cultured cortical 
neurons, in parallel with spine growth and long term potentiation (Je, Lu et al. 
2009). Yet this study was reproduced in vivo studies. 
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A.V. Background: design of site specific cleavage of PKRkin
! In theory, the constitutively active PKRkin can be engineered to be a 
target of a selected protease by replacing an endogenous 13-residue protease-
sensitive site (aa 338-350), that separates residues that make up the catalytic 
site (Dar, Dever et al. 2005), by the target sequence of that protease, if the 
protease does not have other targets in the host organism. The non-structural 
protein 3 (NS3) form Hepatitis C Virus (HCV) is a small monomeric protein with 
an unusual but well characterized substrate specificity (Steinkuehler, Urbani et al. 
1996). It has previously been expressed in mammalian cells without noticeable 
toxicity and it is the primary drug target in the HCV (Huang, Murray et al. 2006). 
In HVC, NS3 forms a complex with a 14-residue strand of its cofactor, NS4A 
protein, and together they process the viral polyprotein into individual 
components. A recombinant protease, NS3/4A, was made by  fusing the N-
terminal proteolytic domain of NS3 to NS4A with a flexible linker.This fusion 
stabilizes the structure and the active site, and substantially increases both the 
half-life and the enzymatic efficiency  (Kim, Morgenstern et al. 1996; Taremi, 
Beyer et al. 1998). Among the cleavage sites of NS3 on HCV polyprotein, the 
NS5A/B junction (DTEDVVCC`SMSY) shows highest efficiency. In a recent study, 
NS3/4A was used as a tool to tag newly  synthesized proteins (Lin, Glenn et al. 
2008). The authors expressed NS3/4A fused to the C-terminal of the protein of 
interest (POI) and N-terminal of a tag, fused via the cleavage site. This way 
NS3/4A cleaved itself off from both the POI and the tag. In the presence of the 
inhibitor, the POI was expressed as fusion with the tag and NS3/4A. In mice, 
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there are two identified targets of NS3 protease, anti-viral response proteins TIR-
domain-containing adapter-inducing IFN-β(Li, Sun et al. 2005) and mitochondrial 
antiviral signaling protein (Johnson, Owen et al. 2007), meaning that in 
transgenic mice with this construct may have compromised immune response. 
NS3/4A is an important candidate for new generation drug development. Several 
drugs have been designed in the recent years and few even were approved by 
Food and Drug Administration as HCV drugs (Romano, Ali et al. 2012). A 
product-derived inhibitor of NS3/4A, BILN 2061, with sub-nanomolar inhibition 
constant, reduces the viral load below detection limit within 48 hours in clinical 
trials (Yee, Farina et al. 2006). The half-life of this complex is estimated in the 
order of seconds (Bartenschlager, Lohmann et al. 1995). The development of the 
drug was stopped in Phase II trials due to cardiotoxicity when administrated in 
high doses over extended periods (Reiser, Hinrichsen et al. 2005). 
A.VI. Background: design of the expression system in mice
! In this method, NS3/4A, PKRkin, engineered to be a target of NS3/4A, 
PKRkin*, and eGFP were expressed in a single mouse as a multicistronic 
construct (Fig A.2.A), each pair flanking a self-cleaving 14-residue proteinase, 
2A, from foot-and-mouth disease virus (FMDV) (Donnelly, Gani et al. 1997). The 
cleavage mediated by this protein is shown to take place during translation by 
ribosome-skipping (Donnelly, Luke et al. 2001). Once 2A is synthesized it cleaves 
itself off from the growing peptide chain fused to the upstream and the translation 
of the downstream protein resumes following the cleavage. 2A is shown to 
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function exclusively in cis and it has no detectable toxicity. The cleavage 
efficiency increases from 80% to 99% when 2A includes its upstream 39 amino 
acids from FMDV polyprotein. This protein has been successfully used in several 
studies as a tool to make multicistronic constructs (de Felipe, Martin et al. 1999; 
de Felipe 2004). Alternatively  NS3/4A and PKRkin*  could be expressed as a 
fusion protein with a flexible linker, allowing proximity of the enzyme to its 
substrate and 1:1 ratio of enzyme and its substrate. NS3/4A in fusion with its 
substrate has been successfully used in vivo (Lin, Glenn et al. 2008). 
In order to make this construct conditionally  expressed in specific cell types, a 
variation of the well established genetic scheme involving Cre/loxP 
recombination was chosen (Sauer 1998). Briefly, in this method, the mice are 
double transgenic with a Cre recombinase that can excise a sequence flanked by 
13 bp long Cre recognition sites, called loxP, or “floxed”; and with the gene of 
interest that is preceded by a floxed “STOP” cassette, made of a selectable 
marker followed by an SV40 early polyadenylation signal sequence, a false 
translational start and a splice donor signal (Lakso, Sauer et al. 1992). The 
Eef1a1 locus, encoding a translation elongation factor, was chosen as a recipient 
site for transgenic knock-in since it is ubiquitously  expressed at high levels and 
shows no phenotype upon deletion of one alleles (Klinakis, Szabolcs et al. 2009). 
The final construct was designed of 5ʼ and 3ʼ homology regions of the first intron 
of Eef1a1 gene locus, a splice acceptor site, a floxed STOP cassette and and the 
multicistronic construct. The rational of the strategy is shown in Fig A.2.B.
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A.VII. Results: NS3/4A cleaves PKRkin* but not PKRkin
! To test the efficiency of proteolysis in mammalian cells, two NS3/4A target 
sequences, junction sequences from NS5A/B (DTEDVVCC`SMSY) or NS4A/B 
(DEMEEC`ASHLPY) were inserted into a fusion of eGFP and GST. These were 
then expressed in 293T cells in a 2A-multicistronic construct containing NS3/4A. 
The day following transfection, when equal amounts of cytosolic extracts were 
assayed with anti-GFP antibody the cleavage of the NS5A/B junction sequence 
was observed to be the most efficient (Fig A.3.A). This also shows that the 2A 
had very high cleavage efficiency, such that the polyprotein was absent in the 
blots. We next asked whether the expression of genes depends on their position 
in the multicistronic construct. In shuffled constructs, we noticed that the gene at 
the first position is always expressed at higher levels than at other positions (Fig 
A.3.B. left panel), while other positions did not affect the expression levels (Fig A.
3.B. right panel). 
The cells were then transfected with multicistronic construct containing PKRkin* 
with NS5A/B junction site. The extracts blotted with an anti-PKR antibody show 
that significantly lower PKRkin*  levels in the presence of NS3/4A, whereas 
PKRkin was not affected (Fig A.3.C). At any concentration tested, BILN 2061 was 
able to induce the expression of PKRkin*, but did not affect the levels of PKRkin* 
in the absence of NS3 or wild type PKRkin. 1 uM BILN 2061 was applied to cells 
at various times and cells were lysed simultaneously. Western blot analysis 
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showed that by 3-4 hours the PKR levels plateau (Fig A.3.D) which 
phosphorylates its target eIF2α.Cells expressing PKRkin were observed to 
remain healthy for at least 3 days.
A.VIII Results: PKRkin* inhibits translation in absence of NS3/4A
! To test the translation inhibition upon drug administration, the 
multicistronic construct with PKRkin*, NS3/4A and eGFP was co-transfected with 
a Luciferase gene from firefly, Luc2p. At all concentrations tested, 16 hours after 
application of BILN 2061, PKRkin* was able to suppress Luciferase activity by 
more than 10-fold compared to a control (Fig A.4.A). PKRkin* had increased 
activity  with respect to wild-type PKRkin, possibly  due to some adaptation or 
resistance mechanisms taking place in the cell, including inherent susceptibility 
of the wild-type PKRkin to endogenous proteases. 
To test the inhibition of global translation, newly synthesized proteins were 
metabolically labeled in a medium containing 35S after starvation. In cells 
transfected with PKRkin* and NS3/4A, translation rate was comparable to that of 
wild-type cells, whereas in the absence of protease translation rate decreased 
substantially (Fig A.4.B,C and D). 
Although metabolic labeling is a robust way of assessing translation rates in 
cultured cells, when this method is applied in vivo in subpopulations of cells, it is 
no longer applicable. This necessitated a cell-specific assay of translation rates. 
Therefore we used eGFP/L10A reporter-ribosomal fusion. This way not only the 
inhibition of translation can be directly assessed by  eGFP levels, but also the 
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gene expression profile at different time points and between different mouse lines 
can be compared, complementary to the information obtained by inhibition of 
translation. We purified RNA from transfected cells with eGFP/L10A as reporter, 
using antibodies against eGFP. High quality of RNA was observed in every 
sample, except when BILN2061, NS3/4A and PKRkin* were present (Fig A.4.E)., 
indicating lack of eGFP/L10A protein.
Since in vivo the effect will vary  depending on the cell type this is expressed and 
the level it is expressed, we sought to design other constructs with varying 
induction levels. To improve kinetics we produced a fusion of NS3/4A/PKRkin* 
and added more target sites to other loops of PKR (a-c in Fig A.5.A). To make a 
self-inducing system we introduced regulatory sequences of genes that are 
upregulated by PKR, such as Atf4, upstream of PKR (Blais, Filipenko et al. 
2004). In parallel we also tested the less efficient NS4A/B cleavage site and used 
the less active forms of the protease, NS3 alone and a T54A mutant NS3 that 
has compromised proteolytic activity  (Lin, Glenn et al. 2008). The drug-induced 
inhibition of translation by some of these constructs is shown in Fig A.5.A. In the 
cells, transfected with the NS3/4A/PKRkin*  fusions carrying NS4A/B and NS5A/B 
cleavage sites, PKRkin* was efficiently cleaved (Fig A.5.B). These and the 
original multicistronic NS3/4A & PKRkin* with NS5A/B site were most suitable for 
genetic studies, since the drug-induction was the most efficient. 
123
124
A.IX. Results: generation and verification of knockin mice  
! This construct was cloned downstream of a floxed STOP cassette and 
targeted to a ubiquitous and high expressing Eef1a1 locus (Fig A.6.A) (Klinakis, 
Szabolcs et al. 2009). Knockin mice were generated, clones that were positive in 
genotyping were confirmed by Southern blotting (Fig A.6.B). These mice can now 
be bred to a mouse line with a specific Cre recombinase expression pattern. 
When these mice were bred to Emx1 BAC-Cre mice (Schmidt, Warner-Schmidt 
et al. 2012), expected eGFP expression patterns was observed in brain sections 
without immunostaining (Fig A.7).
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A.X. Discussion
! This new way of modifying translation rates in vivo offers many 
advantages compared to the pre-existing techniques. First, by using mouse lines 
that express Cre recombinase in specific subpopulation, the requirement of 
protein translation can be tested cell specifically. Second, applying the drug at 
various time points, at various dosages and in specific brain regions the duration, 
level and neuroanatomical extent of inhibition can also be regulated. Conditional 
mice that carry constructs with different induction characteristics can also offer 
additional dosage regulation. Third, since none of the elements that are used in 
the system have invasive side effects, the observed effects are likely  to be the 
direct result of blocking the protein synthesis in the target cell population. Finally, 
since the method is reversible and not invasive, a single animal can be tested 
over various stages in a behavioral paradigm. In addition, the eGFP /L10A tag 
allows direct assessment of gene expression in these cells in comparison to 
other tissues or over different time points. This method is devised to test whether 
protein synthesis is required in selected cell types for different types of memory 
consolidation. However they can be of multipurpose; for example in the case of 
tinnitus, ringing in the ears, which might be related to dysfunction in plasticity 
(Engineer, Riley et al. 2011). 
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A.XI. Materials and Methods: 
Chemicals and construction of recombinant plasmids 
! The gene for HCV polyprotein was kindly provided by Dr. Charles Rice. 
The 2A gene was kindly provided by Dr. Martin Ryan. The PKR gene was a gift 
from Dr. Prerana Shresta and the eGFP/L10A was a gift from Dr Joseph 
Dougherty. eGFP and GST proteins were fused via control linker, or the junction 
sequences from NS5A/B or NS4A/B (DEMEEC`ASHLPY) by chimeric primers 
and overlap extension PCR. PKRkin* was produced the same way. The elements 
of the constructs were amplified using Phusion polymerase (NEB) and cloned 
into peGFP-N1 vector (Clontech) using appropriate restriction enzymes (NEB). 
primer sequence
PKRkin F GAAACAAAGTATACTGTGGACAAGAG
PKRkin R ACATGTGTGTCGTTCATTTTTCTCTG
PKRkin* Rin GTCCAGGTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTC
PKRkin* Fin GCTGCAGCATGAGCTACACCTGGACCGGCAAGAGCAAAAATAG
2A F GTCACCGAGTTGCTTTACCGGATGAAG
2A R CGAGTCCAACCCTGGGCCCTTTTTTTTTAGT
NS3/4A F GGCAGCGTGGTCATTGTGGGCAGGATC
NS3/4A R CTATGGAAACCACTATGCGGGGGGC
eGFP-L10A F CAGCTCCTCGCCCTTGCTCACCAT
eGFP-L10A R ATACAGACGCTGGGGCTTGCCCATG
PKRkin* mF-in CGAGATGGAGGAGTGCGCCAGCCACCTGCCCTACAGCAAAAATAGTTCAAGGTCAAAGAC
PKRkin* mRin GGTGGCTGGCGCACTCCTCCATCTCGTCACTGGTCTCAGGATCATAATC
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PKRkin* 1-Rin CTCATGCTACAGCACACCACGTCCTCGGTGTCATATTTAACACGTTTAATAACGTAAGTCTTTCCGTCAATTC
PKRkin* 1-Fin GACGTGGTGTGCTGTAGCATGAGCTACACCTGGACCGGCAACGAGAAGGCGGAGCGTGAAGTAAAAGCATTG
PKRkin* 2-Rin GTAGCTCATGCTACAGCACACCACGTCCTCGGTGTCCTCGCCTCTTCTTTTTTCAATCCATTGTTC
PKRkin* 2-Fin GTGTGCTGTAGCATGAGCTACACCTGGACCGGCCTAGACAAAGTTTTGGCTTTGGAACTCTTTG
PKRkin* 3-Rin GTAGCTCATGCTACAGCACACCACGTCCTCGGTGTCATTTTTCAGAGATGTTACAAGTCCAAAGTC
PKRkin* 3-Fin GTGTGCTGTAGCATGAGCTACACCTGGACCGGCAAGCGAACAAGGAGTAAGGGAAC
Ns3/4A B-F ATTACGGCCTACTCCCAACAGACGC
Ns3/4A B-R CTATGGAAACCACTATGCGGGGGGC
Ns3/4A C-Fin TCCTGGCGACCTGCGTCAATGGCGTGTGTTGGGC
Ns3/4A C-Rin GCACCATGATAGACAGCCCAACACACGCCATTG
eGFP F CAGCTCCTCGCCCTTGCTCACCAT
eGFP R CTTGTACAGCTCGTCCATGCCGAGAGTGATC
GST F TCCCCTATACTAGGTTATTGGAAAATTAAGGGC
GST R ACGCGGAACCAGATCCGATTTTGGAGGATG
Rluc F GCTTCCAAGGTGTACGACCCCG
Rluc R CTGCTCGTTCTTCAGCACGCG
Purifications were done using PCR extraction kit (Qiagen). The ligations were 
performed with Quick Ligase Kit (NEB) and the products were transformed into 
chemically competent TOP10 cells (Invitrogen) that were grown in LB medium 
(Sigma) in presence of 35 mg/ml Kanamycin (Sigma). The plasmids were purified 
using a Miniprep kit (Qiagen). Every construct was verified by sequencing. 
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The plasmid containing the STOP sequence and the Eef1a1 targeting plasmid 
were kindly provided by Dr. Apostolos Klinakis. The mammalian expression 
constructs were sub-cloned into the gene targeting plasmids as previously 
reported (Klinakis, Szabolcs et al. 2009). The final construct was extracted with 
phenol: chloroform: isoamyl alcohol (25:24:1), precipitated in 70% ethanol and 
dissolved in Tris-EDTA buffer.
Cell culture and transfection
! Unless otherwise stated the cell culture experiments were done the 
following way: 293T cells were grown in a 24-well plate in growth medium 
(Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) to have 90% 
confluency the day of transfection. They were transfected with 1 ug of a 
reference plasmid using 2 uL 293Tfectin (Invitrogen) reagent. The amounts of the 
remaining plasmids were adjusted to have the same molarity per well. Cells were 
lysed on ice in phosphate-buffered saline supplied with 1% TritonX100 (Sigma) 
and inhibitors against proteases (78437, Pierce) phosphatases (78420, Pierce) 
and translation machinery (100 ug/ml cycloheximide, Sigma); and the cytosolic 
extracts were isolated after precipitating the insoluble fraction. The protein 
concentrations were measured using BCA protein assay (Pierce). BILN 2061 was 
kindly provided by Boehringer-Ingelheim Inc (Yee, Farina et al. 2006).  
The Luciferase assay was performed according to instruction manual after cells 
were lysed Dual Luciferase assay kit lysis buffer (Promega).
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Western blotting
! For Western blotting the extracts were denatured in sample buffer 
(Invitrogen) under reducing conditions, separated on a pre-cast Bis-Tris SDS-gel 
(Invitrogen) via electrophoresis and transferred on a PVDF-membrane (Biorad). 
The membrane was blotted with primary antibodies, anti-GFP (gift of Dr. Brian 
Chait), anti-PKR (Abcam), anti-eIF2α (Cell Signaling), anti-phospho-eIF2α (Cell 
Signaling) and anti-tubulin (Abcam). The chemiluminescence was detected by 
the application of the ECL substrate (Pierce) on the appropriate horse-radish-
peroxidase-conjugated secondary antibodies. 
Metabolic Labeling
 To visualize the inhibition of protein synthesis metabolic labeling 
experiments were conducted. 20 hours post transfection with 5 ug PKRkin* 
construct (with or without NS3/4A) and 10 uL reagent cells in 6-well plate were 
labeled with 10 uCi TRAN35S label (MP Biomedicals) for 30 minutes following 30 
minutes of starvation before the addition of the label into L-methionine and L-
cysteine-free DMEM media (Invitrogen). One well was incubated with 
cycloheximide for 10 minutes prior labeling as a control for translation inhibition. 
Equal amounts of protein from extracts were separated by electrophoresis and 
transferred on a membrane. The membrane was dried in 100% methanol and 
analyzed for autoradiography, later it was blotted with antibodies and finally 
stained with Coommassie Plus stain (Pierce). Extracts containing equal amounts 
of protein were added into scintillation liquid (PerkinElmer) and the radioactivity 
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was measured via scintillation counter. The radioactivity was calculated taking 
that of the cells in presence of cycloheximide as zero and that of the wild-type 
cells as 100%.
Quality control of ribosomal RNA
! Two custom made mouse anti-GFP antibodies, clones 19C8 and 19F7 
(Heiman, Schaefer et al. 2008), were captured on Dynal magnetic beads 
(Invitrogen Corporation) coupled with protein L (Pierce). The precleared lysate 
from cells was incubated with antibody coupled beads at 4°C with end-over-end 
rotation for approximately 16 hours. Beads were subsequently collected on a 
magnetic rack, washed three times with high-salt wash buffer (10 mM HEPES 
[pH 7.4], 350 mM KCl, 5 mM MgCl2, 1% NP-40, 0.5mM DTT, 100 μg/ml 
cycloheximide) and RNA was released and purified using Rneasy Micro Kit 
(Qiagen) with in-column DNase digestion. RNA quantity and quality were 
determined with a Nanodrop 1000 spectrophotometer (Wilmington) and Agilent 
2100 Bioanalyzer using RNA 6000 Pico Chip.
Gene Targeting, Southern Blotting and Genotyping
! Gene targeting, generation of knockin mice and Southern blotting was 
conducted by the Gene Targeting Facility at The Rockefeller University, New 
York, NY as previously  described (Klinakis, Szabolcs et al. 2009). Following 
primers were used for genotyping. The PCRs were performed with ChoiceTaq 
(Denville) following manufacturerʼs instructions. 
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primer sequence
β-actin F GGCTGTATTCCCCTCCATCG
β-actin R CCAGTTGGTAACAATGCCATGT
eGFP F GCAGAAGAACGGCATCAAGGT
eGFP R ACGAACTCCAGCAGGACCATG
GA5 F GGACCTTTACTTGGTCACGAGGCATGCCGATG
GA5 R TGCCGGTCCAGGTGTAGCTCATGCTGCAGC
GA4 F GGACCTTTACTTGGTCACGAGGCATGCCGATG
GA4 R CAGGTGGCTGGCGCACTCCTCCATCTCGTC
GA F GGACCTTTACTTGGTCACGAGGCATGCCGATG
GA R CTAGAAGGCACAGTCGAGGCTGATCAGCGAGCTCG
A2G5 F CACCATGGGCAAGCCCCAGCGTCTGTATG
A2G5 R TGCCGGTCCAGGTGTAGCTCATGCTGCAGC
Transgenic mice and visualization of eGFP expression
" All protocols involving animals were approved by the Rockefeller 
University  Institute Animal Care and Use Committee (protocol number #09024) in 
accordance with the National Institute of Health (NIH) guidelines. All mice were 
maintained on a 12 h light/dark cycle and given ad libitum access to food and 
water. The Emx1-Cre and Ntsr1-Cre mice were a gift from Dr Eric Schmidt. The 
eGFP/L10A expression was detected as previously described (Schmidt, Warner-
Schmidt et al. 2012). Mice were deeply  anesthetized and transcardially perfused 
with PBS followed by 4% paraformaldehyde. Brains were dissected and postfixed 
for 1-12  hr at 4°C, cryopreserved in 30% sucrose solution, sectioned on a 
freezing microtome (35  μm sections). All sections were imaged on a Zeiss 
LSM700 confocal microscope.
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Appendix B
A new drug-inducible Cre recombinase
B.I. Aim
! Cre recombinase strategy expanded biomedical research using 
genetically  modified animal models, by introducing spatial control of gene 
modifications. However precise temporal control is still not ideal by the currently 
available strategies. Here we developed a drug-inducible Cre, that can be used 
in a plethora of in vivo gene modifications. 
 
B.II. Background: Cre recombinase and transgenic strategies
! Our ability to design genetically modified mice made previously impossible 
in vivo studies in mammalian organisms possible (Wasserman and DePamphilis 
1993). This technology was advanced by  the use of recombinase switches that 
are utilized to study lethal genes or to isolate phenotypes in adulthood or in 
specific cell populations (Sauer 1998)such as those of the brain (Gaveriaux-Ruff 
and Kieffer 2007; Gong, Doughty et al. 2007). 
Cre site-specific DNA recombinase is a powerful tool for the design of such 
switches simply by inclusion of short recombination sites at the site of genetic 
modification. Cre is a 38 kDa product of bacteriophage P1 where is catalyzes the 
cyclization of P1 plasmid after injection (Sternberg, Sauer et al. 1986), by 
recognizing a 34 bp site, called loxP locus. Cre can recognize two loxP sites in 
opposite orientation and invert the sequence in between; however when it 
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encounters two parallel loxP sites, it excises the sequence flanked by these 
(floxed) and ligates them together. 
Two strategies were developed that enable Cre to turn on or off genes of interest 
(GOI). To turn on genes by Cre, either GOI is reversed between two anti-parallel 
loxP sites, or a floxed sequence is cloned upstream of GOI such that the 
expression of GOI is disrupted (Gu, Marth et al. 1994). For this purpose, a floxed 
“STOP” cassette is used, that is made of a selectable marker followed by an 
SV40 early polyadenylation signal sequence, a false translational start and a 
splice donor signal (Lakso, Sauer et al. 1992). To turn genes off by Cre, an exon 
of GOI can simply be floxed in a way that it does not compromise the expression 
or function of the gene in absence of Cre. 
Although the use of native gene expression profiles to express Cre, provides 
great tissue and cell types specificity, temporal control may not always be 
possible. To achieve this, drug responsive promoters have been used (Gossen 
and Bujard 1992). Elegant strategies were generated by fusing a mutated human 
estrogen receptor (ERT) or progestrone receptor (PRT) to Cre. In absence of 
inducer (tamoxifen or mifepristone, respectively) Cre-ERT or PRT is excluded 
from the nucleus, however when inducer binds ERT or PRT and then Cre can 
penetrate into nucleus (Metzger, Clifford et al. 1995; Brocard, Warot et al. 1997). 
Unfortunately these methods showed interference with endogenous signaling 
pathways, very high background activities or low efficiencies; or they required 
drugs at toxic levels (Brocard, Warot et al. 1997; Kellendonk, Tronche et al. 1999; 
Rossant and McMahon 1999; Garcia and Mills 2002). 
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An ideal inducible Cre recombinase system has three basic features: (1) no basal 
activity  in absence of the inducer, (2) nontoxic inducer and (3) inducer that is 
effective in low doses. With that in mind we used the rational of the drug-
inducible protein function, as explained in Appendix A (A.I.IV) for making a drug-
inducible Cre. The locations to insert cleavage sites on the Cre recombinase 
were selected based on the disordered loops observed on the X-ray structure of 
Cre recombinase (Guo, Gopaul et al. 1997); by  non-inactivating sites that were 
revealed by a previous pentapeptide insertional mutagenesis screen (Petyuk, 
McDermott et al. 2004); and by regions where non-homologous loops were found 
only in homologs of Cre. The selected sites are shown in Fig B.1.A.  
To test the recombination efficiency using one plasmid, we cloned a floxed Luc2p 
after start codon and a Renilla Luciferase gene, RLuc, that is not expressed due 
to frameshift, such that upon excision of floxed region, RLuc is in-frame and 
therefore expressed (Fig B.1.B). We could easily  measure the activity of each 
Luciferase by using a dual-Luciferase reporter assay (Sherf, Navarro et al. 1996) 
and quantify the recombination efficiency by the ratio of two Luciferases. 
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B.III. Results: drug-inducible Cre recombinase
! We have located 8 target sites to introduce the cleavage site as an 
insertion. After the initial screen by Luciferase recombination assay, we observed 
complete abolishment of Cre activity  on some sites (A & D in Fig B.2.A) and no 
sign of cleavage on others . By making various combinations of cleavage sites 
we managed to generate several double and triple mutants that showed high 
induction levels (XY, XG and YGE in Fig B2A). We confirmed our observations in 
Western blots, as well (Fig B.2.B). 
B.IV. Discussion
! The drug-inducible Cre described his strategy has a great potential to 
improve the currently available inducible recombination strategies. With the 
availability of Cre mutants with a variety  of background and induction levels, this 
technique offers a possibility of making transgenic with desired inducibility of Cre. 
This strategy still needs large scale in vivo screens of several transgenic lines, 
however the reward will be very useful for temporally controlled in vivo genetic 
manipulations.
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B.V. Materials and Methods
! The gene for Cre recombinase was a gift of Dr. Shiaoching Gong. the 
plasmid containing the STOP cassette was from Dr Ana Domingos. For all 
protocols, see Materials and Methods from Appendix A. 
primer sequence
Cre F ATGTCCAATTTACTTACCGTACACC
Cre R CTAATCGCCATCTTCCAGCAGGCG
Cre X Rin
GTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTCATTCAACTTG
CACCATGCCG
Cre X Fin GCTGCAGCATGAGCTACACCTGGACCGGCAAGAACCGGAAATGGTTTCCCG
Cre Y Rin GTGTAGCTCATGCTGCAGCACACCACGTCCTCGGTGTCCAGCCCGGACCGACGATG
Cre Y Fin GCTGCAGCATGAGCTACACCTGGACCGGCAAGCGACCAAGTGACAGCAATG
Cre A Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCTACTGCCAGACCGCGCGCCTG
Cre A Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCGTAAAAACTATCCAGCAACATTTGGGC
Cre B Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGTACGTGAGATATCTTTAACCCTGATCC
Cre B Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCAGAATGTTAATCCATATTGGCAGAACG
Cre C Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGCTACACCAGAGACGGAAATCC
Cre C Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCAACTACCTGTTTTGCCGGGTCAG
Cre D Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCAGATGGCGCGGCAACACC
141
Cre D Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCTCAACTCGCGCCCTGGAAG
Cre E Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCCTTAGCGCCGTAAATCAATCGATG
Cre E Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCCAGAGATACCTGGCCTGGTCTG
Cre G Rin GCTCATGCTGCAGCACACCACGTCCTCGGTGTCGCTATTTTCCATGAGTGAACGAACCTG
Cre G Fin GGTGTGCTGCAGCATGAGCTACACCTGGACCGGCCGCTGCCAGGATATACGTAATCTG
Luc2p F ATGGAAGATGCCAAAAACATTAAGAAG
Luc2p R TTAGACGTTGATCCTGGCGCTGG
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